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Chapter 1
Introduction
1.1 The nucleosome and epigenetics
Epigenetics describes the heritable phenotypic changes in an organism that do not arise
from changes in the DNA base sequence. DNA is the genetic bank house in the cell, storing an
immense amount of genetic instruction that allows cells to maintain many biological functions.
The patterns of genetic inheritance are, therefore, dependent on the information contained in
DNA, as well as any epigenetic marks.
The human genome contains three billion base pairs, which encode approximately 30,000
to 40,000 genes. To allow for efficient storage of this enormous size in a cell, approximately 146
base pairs of DNA are wrapped around an octameric structure consisting of two copies each of
the histone proteins H2A, H2B, H3 & H4 to form the nucleosome [1]. The nucleosome therefore
is the simplest unit of DNA storage in a cell. Linker histones (H1) associating with approximately
10-60bp of DNA further package the nucleosomal structure into chromatin fibers (Figure 1.1).
Chromatin fibers further condense into chromosomes. This nucleoprotein structure consisting of
DNA, histone proteins and the linker histones limit the accessibility of DNA.
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Figure 1.1: Duplex DNA is assembled into chromatin fibers. DNA is coiled around histone
proteins forming the nucleosome. Consecutive nucleosomes are linked via linker histones (H1)
and short pieces of DNA which further condense into approximately 30 nM chromatin fibers.
More compacting of chromatin fibers forms the chromatids, which are paired and stored in the
cell as the genetic material. Reproduced with permission from FEBS Letters, 579 (2005) 895898.
A high resolution crystal structure (2.8 Å) of the nucleosome was reported by Luger et al. in
1997. The nucleosomal structure has a disc-like shape, consisting of 1.65 turns of left-handed
superhelical DNA with 145 DNA base pairs wound around a core nucleosome structure (Figure
1.2). This structure revealed that, whereas the C-terminal regions of the histone proteins bind to
DNA and form the nucleosome core, the N-terminal regions are unstructured and are not
involved in formation or stability of the nucleosome core but are critical for chromatin
condensation. Further, the N-terminal tails are rich in basic amino acids. Subsequent studies
later showed that histones are subject to a number of covalent post-translational modifications
[2].
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Figure 1.2: Crystal structure of a nucleosome. The duplex DNA (grey) is wrapped around an
octamer of histone proteins (blue: H3; green: H4; yellow: H2A; and red: H2B). N-terminal lysinerich tails on histones are shown by the red arrows (Luger et al Nature 1997 389, 251-260).
Reproduced with permission from FEBS Let., 579 (2005) 895-898.
To maintain proper functioning in a tissue specific manner, cells have to express gene
products on demand. The central dogma of molecular biology dictates that DNA can act as a
template to make a replica DNA daughter molecule or RNA transcript. RNA biosynthesized this
way is typically further translated into proteins by the ribosome. In addition, for replication, the
DNA daughter molecule is transferred to a new cell, allowing passage and continuity of genetic
information. In addition to replication and transcription, gene recombination, repair, and mitotic
condensation involve

chromosomally bound DNA.

The question arises:

How does

chromosomally bound DNA become available for any of these processes to occur? Cells have
to modulate chromatin structure in order to allow for the accurate execution of these processes
for proper cell functioning. Remodeling of chromatin structure involves a variety of mechanisms.
1.2 Epigenetics: Histone modifications, chromatic remodeling and DNA marks
Post-translational modifications on histones modify the nucleosomal physical structure for
DNA accessibility. Covalent modifications on the DNA and N-terminal histone tails are central to
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epigenetic gene regulation. In contrast to the DNA, which is mainly methylated on cystosine
bases, histone modifications are varied [3, 4]. Key modifications include phosphorylation,
acetylation methylation, ubuquitination, sumoylation, citrulination and ribosylation [3]. Lysine and
arginine residues can be mono-, di- or trimethylated; all of which add complexity to histone
modification patterns. Combinations of these histone modifications can give rise to a specific
histone code that dictates the transcriptional status of associated genes [3]. For instance
combinations of acetylations of H4 K8 and H3 K14, together with phosphorylation of S10 on H3,
gives rise actively transcribed genes [3]. Besides histone modifications, other epigenetic marks
involve modifications on the DNA itself, chromatin remodeling and non-coding RNAs [5]. ATPdependent chromatin remodeling complexes such as the SWI/SNF (SWItch/Sucrose
NonFermantable), ISWI (imitation switch) and CHD (chromodomain helicase DNA-binding)
families of remodelers, are recruited by some histone modifications and eject or move
nucleosomes allowing DNA access [6]. Importantly, a link between histone modifications and
DNA methylation has been reported. Specifically, DNA methylation on CpG islands leads to
transcriptional repression, which is attributed to the recruitment of histone modifiers to promoter
regions by the methyl- CpG-binding protein 2, MeCP2 [4].
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Figure 1.3: Common histone modifications [3]. Schematic representing the nucleosome core
with common post-translantional histone modifications, including: acetyl lysine (acK), methylarginine (meR), methyl lysine (meK), phosphoserine (PS), and ubiquitinated lysine (uK). Posttranslational modifications are represented by colored shapes (legend in bottom left corner).
Reproduced with permission from Curr. Bio., 2004, 14 (14), 546-51.

1.3 Histone acetylation and deacetylation
Histone acetylation is the most abundant and well studied post-translational modification
on histones. Two classes of enzymes, histone acetyl transferase (HAT) and histone
deacetylases (HDAC), mediate the balance between the acetylated and deacetylated states.
Acetylation has a prominent role in disease states and several small molecules have been
created that target both histone enzymes.
HATs use the cofactor acetyl-coenzyme A to transfer an acetyl-group to the ε-amino group
of specific lysine residues on histone proteins (Figure 1.4). The removal of the acetyl group is
catalyzed by HDACs (Figure 1.4).

Acetylation neutralizes the positive charge on the DNA

backbone to loosely bind to the nucleosomal structure, which results in the open chromatin form

6
that is generally associated with actively transcribed genes in euchromatin. Removal of the
acetyl group by HDACs results in positively charged lysine residues capable of ionic bonding
with the back to the negatively charged phosphates on DNA. Deacetylated histones bind tightly
to DNA, making DNA inaccessible to transcription factors and promoting the heterochromatin
form (Figure 1.5).

Scheme 1.1: Acetylation and deacetylation of the ε-amino group on histone proteins.
Histone acetyl transferase (HAT) enzymes catalyze the transfer of an acetyl group from the cofactor acetyl-CoA to lysine residues resulting in a neutral acetyl-lysine. The removal of the acetyl
group is catalyzed by histone deacetylases (HDAC). Deacetylation results in a cationic lysine
residue capable of forming ionic interaction with the anionic phosphate backbone on the DNA.
Acetylation and deacetylation are reversible processes and the key enzymes involved are HATs
and HDACs.
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Figure 1.4: Effect of acetylation and deacetylation of nucleosome on gene transcription.
(A). Acetylation of histones by histone acetyltransfarases (HAT) makes DNA accessible to
transcription factors and gene transcription is on (B). Removal of the acetyl group makes DNA
inaccessible to transcription factors (A) and gene transcription is off. (Picture credit Dr. Pflum)
1.4: Histone deacetylases: Classes, structure and mechanism
1.4.1: Classes of HDAC proteins
Eighteen human HDAC proteins are known to date; these are classified into four main
classes on the basis of size, enzymatic mechanism and sequence homology to yeast proteins.
Class I HDAC proteins are relatively small, ranging from 49-55 kDa and are homologous to the
yeast Rpd3 (Reduced potassium dependence 3). Class I includes HDAC1, HDAC2, HDAC3 and
HDAC8 (Figure 1.5) [7] [8] [9]. The class I HDAC proteins have a metal dependent mechanism,
which will be discussed in detail in section 1.4.2. The class I HDAC proteins are mainly nuclear
and are ubiquitously expressed in many cell types, which is in agreement with their role in cell
cycle regulation in various tissues [7] [10] [11].
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Figure 1.5: Summary in length of HDAC classes. Class I HDACs 1-3 and 8 range from 377448 amino acids. Class II HDACs: 4-7and 9-10 have 669 to 1122 amino acids. The class IV
HDAC11 is 347 amino acids long. Bars depict the length of the protein. The catalytic domains
are shown in blue. Black depicts a nuclear localization domain, N, N-terminus, C, and Cterminus.
HDAC4, HDAC5, HDAC6, HDAC7, HDAC9 and HDAC10 belong to the class II subfamily
and have sequence homology to the yeast HdaI (Histone deacetylase 1) protein and are much
bigger in size (80-131 kDa) than class I [12-15]. Unlike the other class II isoforms, HDAC6 has
two active sites on its N-terminal and C-terminus regions, which can be attributed to an in-shift
gene duplication event [12]. Further, the N-terminus active site is dispensable in HDAC6. On
the other hand, HDAC9 and HDAC10 have two splice variants, which possess deacetylase
activities at comparable levels [15]. The rest of the class II isoforms, HDAC4, HDAC5 and
HDAC7, have a single active site on their C-terminal domains. In contrast to the class I HDACs,
which are mainly nuclear and ubiquitously expressed in several cell types, the class II HDACs
can shuttle from the nucleus to the cytoplasm in response to a specific cell signal, for instance
to participate in metabolic events [16].
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The class IV deacetylase, HDAC11, is a 39 kDa protein and is the only class IV member.
Similar to class I HDACs, HDAC11 has a single active site and is mainly nuclear, but it is
thought to have diverged in evolution much earlier from the other HDAC proteins [17]. Despite
these similarities, HDAC11 is expressed in a tissue specific manner with higher levels seen in
the brain, heart, skeletal muscle and kidneys, suggesting a tissue specific function [17].
Class III HDAC proteins are the sirtuins and are homologous to the yeast Sir2 (Silent
information regulator) proteins and include Sirt1, 2, 3, 4, 5, 6 and 7. Whereas class I, II and IV
display a similar metal-dependent enzymatic mechanism, class III HDACs require NAD+ for
catalysis. In this dissertation the sirtuins will not be further discussed because they have a
different enzymatic mechanism distinct from the other classes and are insensitive to the HDAC
inhibitors of interest in the Pflum lab.
Due to the similarities in catalytic mechanisms among classes I, II and IV HDACs, most
HDAC inhibitors (HDACi) display pan inhibition towards these enzymes with only a few being
selective [18, 19]. This topic will be discussed in details in Section 1.6. Additionally, whereas
class I and II HDACs bind to the mSin3A, RbAp48, N-CoR co-repressors in vivo, HDAC11 does
not associate with these complexes, suggesting that HDAC11 is distinct from the rest of the
metal-dependent HDAC proteins [17]. Importantly, the function(s) of the metal-dependent
HDACs is poorly understood, a current problem in cancer treatment, as will be discussed in
section 1.5.
1.4.2: HDAC structure and catalytic mechanism
As discussed in section 1.4.1, Classes I, II and IV HDAC proteins have a similar metaldependent catalytic mechanism. The crystal structures of a histone deacetylase like protein
(HDLP) from a thermophilic bacterium Aquifex aeolicus, which displays 35.2% sequence
homology to HDAC1, has been used as a model to study class I HDAC proteins. The
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crystallographic structure of HDLP resolved at 2.1 Å in complex with the HDAC inhibitors
suberoylanilide hydroxamic acid (SAHA, Zolinza) and Trichostatin A (TSA), was reported in
1999 (Figure 1.6) [20].

Figure 1.6: Crystal structure of the HDAC-like bacterial homolog (HDLP) in complex with
the HDAC inhibitor SAHA [20]. The phenyl capping group of SAHA projects towards the
solvent exposed region. The hydrophobic linker chain of SAHA is accommodated in the 11 Å
channel (also known as the enzyme pocket). The hydroxamic metal binding group of SAHA is at
the bottom of this channel. The 14 Å channel is located on the other side of the catalytic zinc
metal ion. Reproduced with permission from Nat., 1999, 401 (6749), 188-93.
The HDLP structure revealed that the active site contains a hydrophobic, 11 Å channel that
interacts with the long hydrophobic linker chain in TSA and SAHA or in acetylated HDAC
substrates (Figure 1.7). The aromatic phenyl group of TSA and SAHA are located towards the
solvent exposed region. At the bottom part of the 11 Å channel is a catalytic metal ion that
interacts with the hydroxamic groups of SAHA and TSA (Figure 1.7). The function of the 14 Å
channel is unknown. Several biochemical and computational studies have postulated that the 14
Å channel has two main functions: serving as the exit path for the acetate by-product of the
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deacetylation reaction and a shuttling channel for the catalytic water needed in the active site
(Figure 1.8) [20-22].

Figure 1.7: A schematic representation of Trichostatin A (TSA) in the active site of
HDLP [20]. TSA is in black and the protein is in red. HDLP residues are labeled in red with
their counterparts in HDAC1 indicated in black. Thatched semi-circles indicate van der Waals
contacts between hydrophobic protein residues and TSA. Hydrogen bonds are shown as
green dashed lines. Reproduced with permission from Nat., 1999, 401 (6749), 188-93.
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Figure 1.8: Picture of the internal cavity after deacetylation [21]. (A) After deacetylation, the
lysine chain leaves the 11 Å channel while the byproduct, acetate, passes through the 14 Å
channel (see arrows). (B) After escape of acetate, the catalytic center accepts water through the
14 Å channel and acetylated lysine via the 11 Å channel for the next cycle of deacetylation.
Reprinted with permission from the J. Med. Chem., 2004, 47 (13), 3409-17.
The HDLP structure has been widely used for rational HDAC inhibitor design because the
amino acids in the catalytic domains of HDLP and most metal-dependent HDACs are similar
and highly conserved. From this crystallographic data, a plausible mechanism for metaldependent HDAC proteins was deduced (section 1.4.3, Scheme 2) [20]. In addition to HDLP,
the crystal structures for HDAC2, HDAC3, HDAC4, HDAC7 and HDAC8 have been solved [2326]. The class II HDACs 4 and 7 gave insights into the active sites of class II deacetylases.
HDAC4 is a tetramer unlike monomeric HDAC7, which has a structure very similar to HDLP [23,
24]. The focus of this project is the class I HDAC isoform HDAC1. The crystal structure of the
class I isoform HDAC8 will be discussed further; the class I isoform HDAC2 structure is not
thoroughly detailed [27].
The HDAC8 structure is quite distinct from the HDLP structure. It has a dimeric structure
where the monomers are identical and each binds one Zn2+ and two K+ ions [25]. Similar to the
HDLP structure, the Zn2+ metal ion in the HDAC8 active site coordinates to the hydroxamic acid
part of the inhibitors. The K+ ions are thought to influence the deacetylation reaction of HDAC8.
Specifically, one K+ is located closer to and coordinates with the Zn2+ binding amino acids and is
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therefore likely to influence the correct orientation and properties of bound residues involved in
catalysis (Figure 1.9) [25]. Interestingly, the capping groups of the two inhibitor molecules could
facilitate dimer formation by stacking interactions as well as interactions with nearby residues in
HDAC8. Similar to HDLP, the 14 Å channel is hypothesized to be involved in acetate release
[20, 25].

Figure 1.9: Ribbon diagram of the dimeric structure of HDAC8 shown in yellow (monomer
A) and indigo (monomer B) colors [25]. The bound inhibitors in the two active sites are shown
as sticks packed head to tail. Red=oxygen; blue=nitrogen; orange=sulfur. Carbon is shown in
indigo (molecule A) and yellow (molecule B). Violet spheres, Zn2+ ions; red spheres, K+ ions.
Reprinted with permission from Proc. Natl. Acad. Sci. U S A., 2004, 101 (42), 15064-9.
1.4.3: HDAC reaction mechanism
From the HDLP crystal structure, a plausible deacetylation mechanism for the metal
dependent HDACs was proposed (Scheme 1.2).
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Scheme 1.2: Proposed chemical mechanism for class I, II and IV HDACs [20]. HDLP-active
site residues and their proposed HDAC1 counterparts (in parenthesis) are labeled. Reproduced
with permission from Nat.,1999, 401 (6749), 188-93.
The deacetylation reaction involves catalytic His and Asp residues acting as general
acid/base pairs. A catalytic metal ion (can be Zn2+, Co2+ or Fe2+), which coordinates to the Asp,
the two His residues and a nearby tyrosine residue, form hydrogen bonds to the carbonyl
oxygen making the carbonyl carbon a better electrophile. Water in the active site is activated by
the two histidine residues to attack the carbonyl carbon. The resulting tetrahedral intermediate is
stabilized by the metal ion and the Tyr residue (Scheme 1.2B), and collapses to form the
acetate leaving group and lysine (Scheme 1.2C). This process is followed by restoration of the
active site. Although the active site residues are highly conserved among the metal-dependent
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deacetylases, the class II HDACs, HDAC4, HDAC5 and HDAC7, have a histidine residue in
place of the tyrosine residue (Y297), which explains their reduced deacetylase activities [28].
Further, the class I HDAC8 possesses a mono-valent ion containing second site (K+), which is
close to the active site and is required for HDAC8 stability and deacetylase activity [25]. Due to
the amino acid differences in the active sites of class I versus class II HDACs and the presence
of a second metal in the active site in HDAC8, further work is needed to decipher the similarities
and differences in the catalytic mechanisms of these enzymes. It is important to note that
efforts to understand the active site of the individual HDACs are frustrated by a lack of crystal
structures and the fact that bacterially expressed HDAC proteins are inactive, except HDAC8
[29, 30]. Lack of deacetylase activities for recombinant HDACs might be explained by the
requirement of associated proteins to promote HDAC activity or folding (Section 1.4.3).
1.4.4: HDAC associated proteins
Histone modifying enzymes are usually part of protein complexes that recognize and bind to
specific histone modification(s) and are recruited at promoter regions leading to activation or
silencing of target genes [31]. HATs are part of activator protein complexes. Protein complexes
with intrinsic HAT activities include the GNAT super family found in yeast, humans and mouse;
the MYST family in yeast, humans and drosophila; the complex p300/CBP in various
multicellular organisms; the SRC-1, ACTR and TIF2 family of nuclear receptor coactivators in
humans and mice; TAFII250 in humans and mice, and the TFIIIC transcription factors in humans
[32]. Transcription activators whose function is influenced by histone acetylation include; p53, cMyp, GATA-1, EKLF, E3F, HIV Tat, dTCF and the general transcription factors TFIIE and TFIIF
[32]. Notably, the activity of the tumor suppressor gene p53 in cell cycle regulation and
apoptosis is highly regulated and acetylation is one key regulatory mechanism. In addition,
acetylation of the basal RNA, III machinery, TFIIIC, by the p300/CBP-associated factor PCAF, is
required for transcription initiation, whereby the initiation complex RNA polymerase III-TFIIIB
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binds to the promoter region of DNA, further indicating that acetylation is not tied to histone
proteins only [33].
Similar to HATs, HDACs are part of transcriptional co-repressor complexes in vivo, for
instance the Mi-2-NuRD, RbAp48-mSin3A or mSin3B complexes (known as Sin3 in yeast) and
NCoR (nuclear hormone co repressor)/SMRT (silencing mediator of retinoid and thyroid
receptors) [34, 35]. Mechanistically, HDACs associating with co-repressor complexes at
promoter regions to deacetylate nucleosomal DNA of target transcription factors, leading to
gene repression. The repressor activities of HDAC proteins involve DNA-bound transcription
factors. For example, Mad:Max and Ume6 DNA-binding transcription repressors interact with
the mSin3A/B complex which in turn recruits the mammalian deacetylases, HDAC1 or HDAC2,
leading to gene repression [36]. Transcriptional repression by HDAC1 associating with the MadMax heterodimer, is essential for suppression of cell transformation, which ties HDAC1
deacetylase activity to cancer formation [37].
1.5: HDAC proteins in cancer
Aberrant epigenetic coding can lead to diseased states notably cancer, neuron-diseases,
inflammation, and metabolic disorders [38-40]. Granted, clinically relevant therapies targeting
epigenetic marks on histone proteins and DNA are currently in use and a lot more are in clinical
trials, which make the epigenome a relevant area of research [41]. HDAC proteins have been
implicated in a number of diseases, most notably cancer. Cancers are one of the leading
causes of death not only in the United State but also in many other countries, according to the
World Health Organization. But despite the isolation and identification of the various HDAC
isoforms, the individual functions of each HDAC isoform are poorly understood. However,
overexpression of HDAC proteins has been observed in several cancers. The class I HDAC
proteins, HDAC1, HDAC2, HDAC3 and HDAC8, are overexpressed in a number of cancers.
HDAC1, HDAC2 and HDAC3 are overexpressed in colorectal cancer and higher levels of
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expression correlate with reduced patient survival [42, 43]. Further, inhibiting HDAC1, 2, and 3
expression by short interfering RNAs reduces tumor growth [43]. In patients with gastric cancer,
HDAC1, HDAC2 and HDAC3 proteins are up regulated and higher levels of expression were
seen in patients with advanced stage cancer suggesting that overexpression advanced tumor
growth and aggressiveness [44, 45]. HDAC3 is over expressed in patients with lung cancer, as
shown by gene micro-array profiling studies in lung cancer patients [46].
A study involving prostate carcinomas showed that HDACs 1, 2 and 3 are up regulated and
higher expression levels are associated with tumor cell proliferation and differentiation [47, 48].
HDAC1 is over expressed in pancreatic cancers and regulates the activity of the hypoxia
induced transcription factor α, with higher levels of HDAC1 expression correlating to a decrease
in patient survival [49]. Overexpression of HDACs 1 and 2 correlates with cervical dysplasia
and invasive carcinoma [50]. Children with neuroblastoma have higher levels of HDAC8 and
disease progression and death correlates with increasing HDAC8 expression levels [51].
Overexpression of the class II HDAC 4 and 6 is seen in breast cancer tumors with HDAC6
shown to be an estrogen-maintaining gene in patients with breast cancer [52]. Further, high
levels of endogenous HDAC6 augment breast cancer motility and invasion [52]. HDAC6 is over
expressed in oral squamous cell carcinoma [53]. HDACs 5 and HDAC 7 are up regulated in
colorectal cancer [42].
Despite the observed overexpression patterns of HDAC proteins in several cancers, little is
known about the mechanisms via which HDAC overexpression lead to cancer formation and
maintenance. Aberrant cell growth and proliferation are hallmarks for tumor genesis and HDAC1
plays a crucial function. Specifically, HDAC1 is critical for proper cell differentiation and
regulation of cell cycle check point genes [54]. Inhibition of HDAC1 and HDAC3, using small
interring RNAs, led to a reduced proliferative phenotype in HeLa cells suggesting that HDAC1
and 3 regulate the proliferation of cancer cell [55].

A similar study showed that siRNA
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knockdown of HDAC1 and HDAC2 in prostate cancer cells renders them anti-proliferative and
the cells fail to grow in vitro, further proving that HDAC1 and HDAC2 participate in maintaining
proliferation of cancer cells [43]. These combined studies show that overexpression of HDAC
proteins in cancer cells generally renders them proliferative. This phenomenon can be attributed
to transcriptional repression of tumor suppressor genes and cell cycle check point genes by
HDACs [56].
Apart from regulating the proliferative state of tumors, HDAC proteins have been implicated
in multi drug resistance. siRNA mediated inhibition of HDAC1 in drug resistant neuroblastoma
cells rendered the cells sensitive to drug treatment in vitro [57]. In addition, HDAC proteins are
indicators in the control of the biology of cancer cells by inhibiting apoptosis, angiogenesis of
tumor cells from dormant to malignant states, cancerous cell migration and invasion,
proliferation and dedifferentiation of cancerous cells. Therefore, HDAC inhibitors have been
explored as potential anti-cancer drugs.
1.6: HDAC Inhibitors are cancer drugs
Because of their involvement in cancer biology, small molecules targeting HDAC proteins
are attractive anti-cancer agents. HDAC inhibitors (HDACi) exert their inhibitory effects via
binding to the active site pocket and the catalytic metal ion [58]. Two HDAC inhibitors,
suberoylanilide hydroxamic acid (SAHA, Zolinza, Varinostat) and FK-228 (a depsipeptide) have
been approved by the FDA for the treatment of cutaneous T-cell lymphoma (Figure 1.10) [5961]. Several HDACi are also in clinical trials for cancer treatment [62]. But, because the metaldependent HDAC proteins have conserved binding pockets and catalytic residues, most HDACi
interact with most, if not all, of the HDAC family. Efforts to characterize the inhibition patterns of
HDACi are complicated by the fact that most recombinant purified proteins are inactive [63]. The
observed inactivity with recombinant HDACs can be explained by the fact that HDAC proteins
require associated protein partners to remain active, that are lacking in recombinant proteins.
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Non-selective HDAC inhibitors (pan inhibitors) are problematic due to the involvement of
HDAC proteins in important cellular functions, and patients therefore typically experience a lot of
side effects. On the other hand, pan-inhibitors have been very useful in characterizing HDAC
proteins and elucidating their functions in cancer cells.

Figure 1.10: Structures of the HDAC inhibitors SAHA, TSA, MS-275 and FK-228.
HDACi are not only useful as anti-cancer agents but have been widely used as chemical
tools to study HDAC proteins. The HDAC inhibitor trapoxin was used to identify and isolate the
first human HDAC protein, human HDAC1, from nuclear cell extracts, paving the way for
identification of the rest of the human HDAC family isoforms [7]. HDACi are indispensable tools
in HDAC chemistry and the most commonly used ones are TSA and SAHA (Figure 1.10). The
usage of HDACi as chemical tools has been demonstrated in many studies. For instance,
treating murine erythroleukemia cells with HDAC inhibitors induced cell differentiation [64].
Malignant colorectal cancer cells displayed apoptotic effects upon treatment with the HDAC
inhibitors TSA and butyrate [65]. The expression patterns of multiple genes involved in cell
proliferation, cell differentiation and apoptosis were influenced by HDAC inhibitors, as shown by
gene profiling studies [66, 67]. In vitro studies with HDAC 1, 2 and 3 treated with HDAC
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inhibitors FK-228 and SAHA reduced ovarian cell growth and this was also observed using
siRNA silencing [68].
1.7: This thesis project
To develop better anti-cancer drugs targeting HDAC proteins, more studies with HDAC
proteins need to be done. Specifically, the individual roles of each HDAC isoform and their
contributions to cancer are critical to aid in the design of isoform selective inhibitors. The long
term goal of the HDAC project in the Pflum lab is to determine the individual roles of
each HDAC protein and their contribution to cancer formation. As a first step towards
achieving this goal, studies in this thesis project focus on HDAC1. HDAC1 is an attractive target
for anti-cancer drugs because of its role in regulating cell proliferation and cell cycle, the main
events that can lead to cancer development (see discussion in section1.6).
Due to a lack of crystallographic structural information on HDAC1, mutagenesis studies are
a good alternative to give information on the involvement of amino acid residues in the active
site on HDAC1 deacetylase activity. As discussed in section 1.4.2, the active site contains an 11
Å hydrophobic channel where the long hydrophobic linker region of TSA and SAHA is
sandwiched. Mutagenesis studies in this channel demonstrated that most of the amino acids
within are crucial for deacetylase activity (Chapter 2, section 2.2.1) [69]. A 14 Å exit channel is
next to the active site and has been hypothesized to be the exit patch for the acetate byproduct
of the deacetylation reaction. Studies outlined in the second chapter of this dissertation
seek to understand the roles of the amino acids in the 14 Å channel of human HDAC1
using alanine scanning.
The third chapter of this thesis focuses on efforts towards understanding the involvement of
HDAC proteins in cancer formation using small molecule HDAC inhibitors. Previous methods
used to study HDAC1 include genetic methods, such as siRNA and knockout embryonic stem
cells [54, 55]. HDAC1 knockout caused lethality on embryonic day 9.5 in mice, whereas siRNA
required 48 hours time during which HDAC2 compensated for HDAC1. Therefore, genetic
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methods are not suitable for characterizing HDAC1 in cancer biology. Small-molecule inhibitors
are excellent alternatives to genetic methods. For example, small molecules influence protein
activity quickly and do not give the cell time to express proteins, particularly other HDAC
isoforms that might compensate for the abolished activity. It is also possible to evaluate a dosedependent effect for partial inhibition as opposed to total inhibition. Additionally, only the active
site of the enzyme is affected, having the advantage of not affecting protein-protein associations
which might be crucial to activity. With the advantages of inhibitors, the use of modified inhibitor
analogues to characterize the individual functions of HDAC1 and their relevance to cancer
formation is practical. Towards this goal, efforts to create the first HDAC1-inhibitor bumphole pair will be detailed in the third chapter.
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Chapter 2
2.1: Mutagenesis studies in HDAC1 14Å channel
HDAC1 is an attractive anti-cancer target (see section 1.5 chapter 1) and therefore HDAC1selective inhibitors would be valuable tools for studying the involvement of HDAC1 in cancer
formation and provide better anti-cancer drugs. The lack of structural information for HDAC1
has frustrated efforts to design selective inhibitors. Currently, HDAC inhibitor design relies on
the crystal structure of a histone deacetylase like-protein (HDLP), which displays 35.2%
sequence homology to HDAC1 [20]. A HDAC1 homology model based on HDLP revealed that
the active site contains a hydrophobic 11 Å channel with a catalytic metal ion at the bottom of
the channel [69]. HDAC inhibitors have been designed that fit in this long channel by making
favorable hydrophobic interactions with amino acids lining the channel.
At the bottom of the active site and next to the catalytic metal ion is the 14 Å internal cavity
whose function remains unclear [20, 21]. The 14 Å channel of Class 1 HDAC isotypes has been
hypothesized to be the exit cavity for acetate following deacetylation [20, 21, 70]. The amino
acids lining this cavity are very similar suggesting the role of the cavity is relevant to all class I
HDACs. Computational and homology model studies identified charged amino acids that are
likely to facilitate acetate escape by forming favorable ionic interactions (Figure 2.1) [71]. In one
study, docking showed that both acetate and acetic acid localize next to the metal ion, R16 and
R27 in HDLP (Figure 2.1) [21]. These interactions were not present in the 11 Å channel (Figure
2.2) [21]. In contrast, similar studies with N-hydroxyacetamide, which is similar to HDAC
inhibitors SAHA or TSA, revealed less binding.
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Figure 11: Docking acetate in the 14 Å channel of HDLP revealed important amino acids
involved in acetate escape [21]. Acetate localized next to R16 (indicated by III) and R27
(indicated by II) in HDLP presumably by forming ionic interaction, but failed to localize next to Zn
(I) or in the 11 Å channel Similar results were shown with acetic acid (data not shown). Reprinted
with permission from J. Med. Chem., 2004, 47 (13), 3409-17.
In addition to facilitating acetate escape, the internal cavity may act as an inlet for catalytic
water following deacetylation to restore the active site configuration for the next cycle of
catalysis, as illustrated in Figure 2.2 [21]. Further, residues located towards the solvent exposed
regions of HDAC1 demonstrate flexibility, indicating that side chain movement near the solvent
exposed region of the 14 Å channel could exchange cavity contents with the bulk water for the
next cycle of deacetylation [20, 21].

Figure 12.2: Picture of internal cavity after deacetylation [21]. (A) While the free lysine
chain leaves the 11 Å channel, the byproduct, acetate, passes through the 14 Å cavity (see
arrows). (B) The catalytic center therefore is ready to accept water and an acetylated lysine for
the next cycle of deacetylation. Reprinted with permission from J. Med. Chem., 2004, 47 (13),
3409-17.
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The 14 Å channel has been exploited in inhibitor design. Several isoform selective HDACi
designed to fit the 14 Å channel have been created [18, 19]. In one study, docking MS-275 into
a HDAC1 homology model revealed that a large aromatic substituent on the metal binding
moiety could access the 14 Å channel [19]. In addition, the presence of M30 and C151
suggested that para-thienyl substituted amino benzamide MS-275 derivatives could benefit from
potential sulfur interactions. This led to the synthesis of compounds 1 with an IC50 of 0.02 µM
and 0.5 µM against recombinant HDAC1, and 2 respectively (5-fold selectivity for HDAC1 over
HDAC2) but is non selective towards HDAC3 and 8. Further studies led to the synthesis of
compounds 2 (IC50=0.06 µM for HDAC1 and IC50=0.2 µM for HDAC2) and 3 (IC50=0.05 µM for
HDAC1 and IC50=0.2 µM for HDAC2), which represents 100-400-fold selectivity for HDAC1 and
2 over HDAC3 and 8 (both compounds 2 and 3 have IC50>20 µM for HDACs 3 and 8). The
observed increases in selectivity are attributed to additional beneficial interactions between MS275 derivatives and the enzyme resulting from potential sulfur interactions with amino acids
located in the 14 Å channel.

Figure 13: HDAC1 and 2 selective MS-275 derivatives designed to fit the 14Å channel [19].
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In a separate study, several other HDAC inhibitors designed to fit the 14 Å channel were
created (Figure 2.4) [72]. Compound 4 was 30-fold selective for HDAC1 over HDAC2 (HDAC1
IC50=6 nM and HDAC2 IC50=190 nM) and is only weakly bound to HDAC3 (IC50=27 µM) and
HDAC8 (IC50=31 µM). Similarly, compound 5 was 10-fold selective for HDAC1 (IC50=10 nM)
over HDAC2 (IC50=105 nM) with very weak HDAC3 and 8 affinity (IC50>50 µM). Combined, both
studies suggest that isoform selective HDAC inhibitors can be designed to bind the 14 Å
channel [18].

Figure 14: HDAC1 and 2 selective MS-275 derivatives designed to fit the 14 Å channel [72].
With no structural information for HDAC1, the role of the 14 Å channel in acetate binding and
substrate/inhibitor binding is still unclear. Without crystallographic information, mutagenesis can
offer insight into the influence of amino acid residues in the 14 Å cavity to HDAC1 activity.
2.2: Prior HDAC1 mutagenesis studies in the Pflum lab
Residues lining the 11 Å channel of HDAC1 form hydrophobic contacts with the acetylated
Lys substrate in the active site (Chapter 1, figure 1.7). Amino acids lining the 11 Å channel are
well conserved among the HDAC isoforms suggesting that their roles are relevant to all isoforms
(Figure 2.5). Previous mutagenesis studies in the 11 Å channel of HDAC1 revealed that
residues in this channel influence enzymatic activity (Figure 2.6) [69].
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Figure 15: A Clustal W alignment of the residues lining catalytic domains of class I, II and
IV human HDAC proteins [69]. Amino acid residues located in the substrate binding region (the
11 Å channel) are shown. Highlighted in red are the residues that differ from the most
conserved residue at the specified position. The numbering on top is for HDACI.

Figure 16: A human HDAC1 homology model showing residues lining the 11 Å channel of
HDACI [69]. Channel residues are shown as ball and stick structures. The gray ball shows the
catalytic zinc, whereas the yellow, red and blue represent carbon, oxygen, and nitrogen atoms
respectively. Reproduced with permission from J. Med. Chem., 2008, 51 (18), 5542-51.
To study the 11 Å channel amino acids, a homology model was used to identify nine amino
acids that line this channel in human HDACI. An alanine scan for these nine amino acid
residues identified eight residues crucial for enzyme activity (Figure 2.7) [69]. Specifically,
mutating H28, P29, D99, G149, F150, Y204, F205 and L271 to alanine led to a 62-91%
reduction in HDAC1 enzymatic activity compared to wild type (Figure 2.7A) [69]. The only
exception was the E98A mutant, located in the solvent exposed region of HDAC1, that
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maintained deacetylase activity to levels comparable to HDAC1 (Figure 2.7A [69]. Further,
mutating channel residues did not compromise HDAC1 binding to its associated proteins
(Figure 2.7B). These combined data suggest that residues lining the 11 Å channel govern
substrate binding and that mutations lead to a reorganization of the channel residues which
compromise HDAC1 deacetylase activity.

Figure 17: Residues lining the 11 Å channel of HDAC1 promote enzyme activity but not
protein associations [69]. (A) HDAC1 wild-type or alanine mutants were expressed as FLAGtagged fusion proteins and were immunoprecipitated with anti-FLAG-agarose resin. The
immunoprecipitated proteins were used in fluorescence HDAC assays (histogram). The mean
percent activity of five independent trials compared with that of the wild-type protein (100%) with
standard error is shown. The immunoprecipitated proteins were also separated by SDS-PAGE
and were probed with anti-FLAG (gel image) to ensure that equivalent protein quantities were
used (Figure A.1). (B) Immunoprecipitated proteins in part A were further probed with antimSin3A, anti-RbAp48, and anti-FLAG to assess protein association. Reproduced with
permission from J. Med. Chem., 2008, 51 (18), 5542-51.
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Studies outlined in this chapter were geared towards understanding the importance of amino
acid residues in the 14 Å internal cavity for HDAC1 activity. We used alanine scanning
mutagenesis and substitution mutagenesis to determine the importance of channel residues to
HDAC1 activity. Further, we performed an acetate competition assay to determine whether
alanine mutants affect HDAC1 binding to acetate. Our results suggest that amino acids lining
the 14 Å channel are important to maintain HDAC1 catalytic activity and that mutating them to
alanine leads to a loss in activity. The acetate competition experiments reveal that several
residues affect the interaction of HDAC1 with acetate.

The mutagenesis studies identified

amino acid residues involved in acetate or inhibitor binding and will aid in HDAC1 inhibitor
design that includes the 14 Å channel.
2.3: Results
2.3.1: Residues in the 14Å channel of HDAC1 are critical for activity
Computational and homology studies have predicted that in HDAC1 Y23 (aligned with R16
in HDLP) and R34 (aligned with R27 in HDLP) form a charged pocket in the 14 Å channel and
bind to and thereby stabilize the acetate by-product of the deacetylation reaction (Figure 2.1 and
2.2) [21]. The polar residues C151 and Y24 line the other side of the cavity and are likely to
influence acetate binding and restoration of the active site configuration (Figure 2.2).

In

addition, these four amino acids might influence substrate binding and orientation of the active
site due to their close proximity to the active site. Not surprisingly, C151 and R34 are strictly
conserved among all class 1 isoforms, while Y23 and Y24 maintain 75% similarity (Figure 2.8B),
indicating that the role of the 14 Å channel is relevant to all class 1 HDACs.

29

Figure 18: (A) Amino acid residues in the acetate-escape patch of HDAC1. The four amino
acids (stick structures) lining the 14 Å channel of an HDAC1 homology model are shown. (B)
Amino acid residues lining the 14 Å channel are shown for class I HDACs and HDLP. The
catalytic domains of class 1 HDAC isoforms were aligned used Clustal W. Residues highlighted
in red differ at Y23 (HDAC1) and Y24 (HDAC1).
To determine the influence of Y23, Y24, R34 and C151 in the 14 Å channel on HDAC1
enzymatic activity, each amino acid was individually mutated to alanine. Alanine mutants or the
wild-type

were

expressed

in

T-Ag

Jurkat

cells

as

FLAG-tagged

fusion

proteins,

immunoprecipitated with α-FLAG agarose beads, and tested for deacetylase activity using an in
vitro fluoresence assay (Figure 2.9). The catalytically inactive mutant H141A was included for
comparison purposes [20].
These alanine mutants each significantly influenced HDAC1 catalytic activity. The highly
conserved R34 and C151 alanine mutants demonstrated only 31±6.5% and 21±4.5% remaining
activity, compared to the wild type (100%) and which is comparable to the inactive H141A
(19%±1.5). Mutating the two Tyr residues, Y23 and Y24 to alanine led to a 34± 7.0% and 25±
6.0% catalytic activity, respectively, compared to the wild type (100%). The HDAC1 homology
model predicts that R34 and C151 are closer to the active site than Y23 and Y24, which are
closer to the solvent exposed region of the 14 Å channel (Figure 2.8). These alanine scan
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results suggest that Y23, Y24, R34 and C151 are critical to maintain the catalytic activity of
HDAC1.

Figure 19: Y23A, Y24A, R34A and C151A mutants affect HDAC1 deacetylase activity, but
not protein association. (A) Wild type or mutant proteins were expressed in T-Ag Jurkat cells
as FLAG-tagged fusion proteins, immunoprecipitated with anti-FLAG-agarose beads, and tested
for catalytic activity using an in vitro fluorescence assay (histogram) or separated on SDS-PAGE
and probed with anti-FLAG antibody (gel image). The histogram shows the mean percent of at
least four independent trials, which were normalized to wild type deacetylase activity (set to
100%). The standard error is shown as error bars (Table A.1). (B). Immunoprecipitated wild type
and alanine mutants in A were further probed with anti-FLAG, anti-RbAp48 and anti-mSin3A to
assess protein association.
To study the influence of other amino acids lining the 14 Å channel on catalytic activity, the
HDAC1 homology model was used to identify V19, M30, I35, R36, S113, L139 and Y303 for
further analysis (Figure 2.10). With the exception of R36, most of these amino acids are
hydrophobic or polar, and are therefore not expected to bind to acetate. Because of their
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location in the 14 Å channel and proximity to the active site, these seven amino acids may
influence substrate binding or restoration of the active site configuration.

Figure 20: Residues in the 14 Å channel of HDAC1 (A).The seven additional amino acids
(stick structures) lining the 14Å channel of the HDAC1 homology model are shown. (B)
ClustalW alignment of the amino acids noted in A. Highlighted in red are the residues differing
at each position.
To determine the influence of seven additional amino acids in the 14 Å channel on HDAC1
enzymatic activity, each amino acid was individually mutated to alanine, over expressed,
immunoprecipitated, and tested for activity as discussed earlier. These alanine mutants all
significantly reduced HDAC1 catalytic activity (Figure 2.11). The strictly conserved Y303 alanine
mutant displayed 6.7±1.5% remaining activity relative to the wild type HDAC1 (100%). The
homology model predicts that Y303 is close to the active site, near the catalytic metal ion
(Figure 2.10). The dramatic loss of activity in the alanine mutation suggests that Y303 promotes
HDAC1 deacetylase activity. The alanine mutations of hydrophobic residues V19, I35 and L139,
which display 50% similarity among the class 1 isotypes, displayed between 5-39% deacetylase
activities suggesting that all are important for HDAC1 deacetylase activity. Mutation of the
amino acids M30 and S113 to alanine resulted in 19±6% and 62±4% deacetylase activities. The
R36A mutant had 25±4% remaining activity, which is comparable to the inactive H141A mutant
(19±1.5%). The combined mutagenesis data suggests that except for S113, the other six amino
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acids in the 14Å channel are critical for maintaining HDAC1 enzymatic activity but do not appear
to be involved in acetate release.

Figure 21: The 14 Å channel alanine mutants affect HDAC1 deacetylase activity, but have
no effect on protein association. (A) Wild type or mutant proteins were expressed in T-Ag
Jurkat cells as FLAG-tagged fusion proteins, immunoprecipitated with anti-FLAG-agarose
beads, and tested for catalytic activity using an in vitro fluorescence assay (histogram) or
separated on SDS-PAGE and probed with anti-FLAG antibody (gel image). The histogram
shows the mean percent of at least four independent trials that were normalized to wild type
deacetylase activity (set to 100%). The standard error is shown with error bars. (B) Coimmunoprecipitation of alanine mutants in A with, anti-FLAG, anti-RbAp48 and anti-mSin3A to
assess protein association.
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2.3.2: HDAC1 rescue mutants are inactive
According to computational and homology studies, the strictly conserved R34 is located
closer to the active site, whereas the poorly conserved R36 residue is adjacent to R34 but
farther from the active site in HDAC1 (Figures 2.6 and 2.8) [69]. The acetate by-product of the
deacetylation reaction could form favorable ionic interactions to R34 and Y23 (similar to R16 in
HDLP) located farther from the active site and close to the solvent exposed region of the 14 Å
channel. These computational studies predict that acetate is exchanged with the bulk water
outside the channel. Substitution of a similar charged functional group capable of forming ionic
bond at R34 or R36 in HDAC1 could maintain enzymatic activity. Similarly, the C151 residue
(located next to the catalytic metal ion and in the 14 Å channel) could be replaced by serine with
a similar polar functional group, which could maintain interactions with acetate or the active site.
Additionally, to probe the importance of the aromatic phenyl group of Y23, 24 and 303 in
HDAC1, Y23F, Y24F and Y303F substitution mutants were created. In this case, if aromaticity is
critical, aromatic amino acids should replace tyrosine.
To test the rescue mutations, Y23F, Y24F, R34K, R36K, C151S and Y303F single point
mutants

were

expressed

in

T-Ag

Jurkat

cells

as

FLAG-tagged

fusion

proteins,

immunoprecipitated with FLAG-agarose beads, and tested for deacetylase activity using an in
vitro fluoresence assay, as described earlier. The substitution mutants were unable to restore
HDAC1 catalytic activity except for the Y24F mutant (Figure 2.12). R34K, R36K and C151S
HDAC1 mutants demonstrated 17±3.0%, 33±3.5% and 30±1.0% remaining activity respectively.
Mutating the residues Y23, Y24 and Y303 to Phe led to 12±3.5%, 56±9.0% and 38±4.0%
deacetylase activity respectively. Collectively, these mutagenesis data suggest that Y23, Y24,
R34, R36, C151 and Y303 are uniquely suited to promote HDAC1 deacetylase activity, and that
F partially substitutes for Y24 and Y303 in HDAC1.
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Figure 22: HDAC1 Y23F, Y24F, R34K, R36K, C151S and Y303F substitution mutants are
inactive. (A) Wild type or mutant proteins were expressed in T-Ag Jurkat cells as FLAG-tagged
fusion proteins, immunoprecipitated with anti-FLAG-agarose beads, and tested for catalytic
activity using an in vitro fluorescence assay (histogram) or separated on SDS-PAGE and probed
with anti-FLAG antibody (gel image). The histogram shows the mean percent of at least three
independent trials that were normalized to wild type deacetylase activity (set to 100%). The
standard error is shown as error bars (Table A.2). (B) Co-immunoprecipitation of mutants in (A)
with anti- FLAG, anti- RbAp48 and anti-mSin3A to assess protein association.
2.3.3: Mutation of amino acids lining the 14 Å channel of HDAC1 does not disrupt protein
association
The mammalian co-repressor complexes mSin3A and RbAp48 tie HDAC1 to promoterbound transcription factors, leading to transcriptional gene silencing (discussed in section 1.4.3
chapter 1) [70, 73-75]. The binding of HDAC1 to co-repressors not only recruits the deacetylase
to promoter regions but also leads to an increase in deacetylase activity [73]. Our results
suggest that alanine and substitution mutants abolish HDAC1 activity. It is therefore possible
that mutations lead to protein misfolding and/or that mutant proteins fail to bind to co-repressor
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complexes. To test whether the loss in activity observed in mutant proteins was a result of
failure of the mutant proteins to bind to its associating partners, biochemical purification was
performed. Alanine and substitution mutants were immunoprecipitated with FLAG-agarose
beads, separated on SDS-PAGE, and probed with anti-mSin3A or anti-RbAp48 antibodies.
Alanine and substitution mutants displayed equal co-immunoprecipitation activities independent
of deacetylase activity (Figure 2.9B, 2.11B and 2.12B). The inactive H141A recovered similar
levels of mSin3A and RbAp48 comparable to the wild type as previously reported [69].
Collectively, our results suggest that the loss in activity in 14Å channel is not due to a failure of
mutant proteins to bind to the co-repressor complexes.
2.3.4: R34 and R36 affect interaction of HDAC1 with acetate
To facilitate passage of acetate through the 14 Å channel, computational studies predicted
that charged amino acids R34 and R36 in HDAC1 would form favorable ionic/hydrogen bond
interactions with acetate [21]. Polar residues Y23, Y24, C151 could also hydrogen bond to
acetate [70].Further, side chain movement of Y23 and Y24 located towards the solvent exposed
region of the 14 Å channel could help exchange acetate with the bulk water solvent [21, 70]. Our
mutagenesis results demonstrate that mutations of the amino acids thought to bind to acetate
abolish HDAC1 enzymatic activity.
To determine the influence of mutant proteins to acetate binding in HDAC1, acetate
inhibition of the activities of Y23, Y24, R34, R36, and C151 mutants were determined and
compared to wild type. The F205Y mutant located in the 11 Å channel was included as a control
because it should not affect acetate binding [69]. Mutant or wild type proteins were
immunoprecipitated with FLAG-agarose beads and the extent of inhibition by acetate was
determined at constant substrate concentration. All 14 Å tunnel mutations displayed altered
acetate inhibition. The R34A and R36A mutants displayed 1.7 and 2.8 fold reduced IC50 values
(12 mM and 15 mM, respectively) compared to the wild type (7.2 mM) and F205Y (7.5 mM)
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controls (Figure 2.13). Similarly, the Y23A, Y24A and C151A mutants displayed close to 2-fold
reduction in acetate binding compared to wild type (Figure 2.14). Collectively, these acetate
competition data suggest that both charged and polar amino acid residues in this channel
influence HDAC1 binding to acetate and confirms the involvement of these amino acids in
acetate binding or release.

Figure 23: R34 and R36 mutations affect HDAC1 binding to acetate. Wild type or mutant
proteins were expressed in T-Ag Jurkat cells as FLAG-tagged fusion proteins,
immunoprecipitated with anti-FLAG-agarose bead, and tested for catalytic activity in the
presence of varying concentrations of acetate (0-200 mM). The standard error for at least
three trials is shown. (Table 1.1).
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Table 1.1: IC50 values on acetate inhibition of HDAC1 and mutant proteinsa
HDAC1

IC50 (mM)

Wild type

7.2 ± 0.5

Y23A

21 ± 2

Y24A

19 ± 1

R34A

12 ± 0.3

R36A

15 ± 1

C151A

13 ± 1

F205Y

7.6 ± 1.1

a

Calculated from at least three trials; errors are the standard error of the mean.

Figure 24: Y23, Y24 and C151 affect HDAC1 binding to acetate. Wild type or mutant proteins
were expressed in T-Ag Jurkat cells as FLAG-tagged fusion proteins, immunoprecipitated with
anti-FLAG-agarose bead, and tested for catalytic activity in the presence of varying
concentrations of acetate (0-200 mM). The standard error for at least three trials is shown
(Table 1.1).
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2.4: Discussion
The 14 Å channel of Class 1 HDAC isotypes has long being hypothesized to be the exit
cavity for acetate release by deacetylation [20, 21, 70]. The amino acids lining this cavity are
very similar among the HDAC isoforms, suggesting the role of the cavity is relevant to all
HDACs proteins. In one study, docking showed that both acetate and acetic acid localize next to
the metal ion, and amino acids R16 and R17 in HDLP. In contrast, in similar studies, Nhydroxyacetamide, which is related in structure to HDAC inhibitors SAHA or TSA, was bound to
the 11 Å channel,but less to the 14 Å channel [21]. In addition, amino acids located towards
the solvent exposed regions of HDAC1 demonstrate flexibility, indicating that side chain
movement of these amino acids could help exchange cavity contents with bulk water for the
next cycle of deacetylation [20, 21]. To date, no experimental data confirm these speculations
with HDAC1.
An alanine scan was used to determine the influence of amino acid residues lining the 14 Å
channel of HDAC1 in enzymatic activity and binding to acetate [22, 69]. HDAC1 V19A, Y23A,
Y24A, M30A, R34A, I35A, R36A, L139A, C151A and Y303A mutants reduced HDAC1
deacetylase activity significantly to levels ranging from 6 to 34% compared to the wild type. The
S113A mutant, which is located near the solvent exposed region of the internal cavity, maintains
significant deacetylase activity at 61% compared to the wild type (100%). Because polar and
charged residues lining the 14 Å channel of HDAC1 are implicated in acetate binding and
release, more conservative mutations were examined to see if they could restore deacetylase
activity. These mutants also displayed reduced deacetylase activities suggesting functional
group specificity. Y24F is the only mutant that maintained a significant deacetylase activity at
56% compared to that of the wild type. These combined mutagenesis studies suggest that the
14 Å channel is critical to maintain HDAC1 activity and influence acetate binding and release.
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Mutating the 14 Å cavity residues does not globally affect HDAC1 structure as shown by the
protein association studies. The loss in enzymatic activity for mutant proteins can therefore be
attributed to two possibilities. One, mutating channel residues might influence substrate binding
and govern the organization of the active site residues, which ultimately affect HDAC1 activity.
Alternatively, mutating channel residues might influence the release of the acetate by-product.
To probe this hypothesis further, we determined the influence of mutation on HDAC1 binding to
acetate. Both polar and charged residues showed a two-fold reduction in the half-maximal
inhibition by acetate compared to the wild type. It is likely that mutating these residues remove
key contacts required for acetate binding and release. These findings are consistent with
previous work on HDAC8, where acetate competition assay with recombinant HDAC8 R37A
resulted into 160-fold difference in IC50 values (HDAC8R37A IC50 of 400 mM versus the HDAC8
wild type IC50 of 2.5 mM) [22]. The small differences observed here with HDAC1 could be a
result of mammalian proteins versus bacterially-expressed proteins in the two separate studies.
Combined, our results indicate that the 14 Å channel mutants do not significantly alter the active
site configuration, but rather affect the substrate binding and acetate release.
HDAC1 has been linked to certain cancers, making it an attractive target for cancer therapy.
Characterization of HDAC1 structure will aid in drug-design efforts and will facilitate the
understanding of its involvement in cancer formation. In addition, HDAC1 selective inhibitors
may be valuable cancer therapeutics. The lack of structural information on the HDAC1 active
site has frustrated efforts to design HDAC1 selective inhibitors. Structural characterization of
HDAC1 has been hindered by lack of active enzyme from heterologous bacteria culture [76]. As
an alternative, mutagenesis offers insight into the influence of amino acid residues in the
enzyme pocket to HDAC1 activity. The combined mutagenesis data confirm the importance of
V19, Y23, Y24, M30, R34, I35, R36, S113, L139, C151 and Y303 in the 14 Å channel of
HDAC1, as predicted earlier[21,71].
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The mutagenesis studies in this work will aid in the design of HDAC1 selective inhibitors.
Importantly, selective HDAC1 inhibitors designed to fit the 14Å channel have been created [19].
Subtle differences in amino acids give rise to distinct channel regions and can be exploited to
design selective HDAC1 inhibitors as previously reported [19, 71]. The acetate competition
results suggest that designing HDAC1 inhibitors with acetate mimics targeting interactions with
Y23 can create a HDAC1 selective inhibitor. Future inhibitor design which includes the 14Å
channel will benefit from these findings.
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2.5: Experimental procedures
2.5.1: General biochemical equipment
Equipment available in the Pflum lab includes centrifuges (Eppendorf models 5415D and
5810R), bacterial incubator/shaker (New Brunswick Scientific C25 Incubator Shaker Classic
Series), Tecan GENios Plus spectrophotomer, Biorad gel electrophoresis systems and an
Eppendorf Mastercycler Gradient.
2.5.2: Single point mutagenesis
Asymmetric was used to create HDAC1 single-point mutants using the primers shown
below; mutants were cloned into the pBJ5HDAC1-Flag expression plasmid using Not1 and
EcoR1 restriction sites [70]. All mutants were confirmed by DNA sequencing. The primers used
were as follows (mutation bolded):
pBJ5 Not1 start: GCCAGAATGCGGCCGCATGGCGCAG
pBJ5 153 rev: TATCATGTCTGGATCCGG
HDAC1 V19A rev: CATCCCCGTCGTAGTAGTAACAGAC
HDAC1 V19A for: GTTACTACTACGACGGGGATGCTGGAAATTACTATTATGG
HDAC1 Y24A rev: GTAATTTCCAACATCCCCG
HDAC1 Y23A for: CGGGGATGTTGGAAATTACGCATATGGACAAGGCCACCCAATG AAGCC
HDAC1Y23Ffor: CGGGGATGTTGGAAATTACTTCTATGGACAAGGCCACCCAATGAAGCC
HDAC1 Y24A for: CGGGGATGTTGGAAATTACTATGCAGGACAAGGCCACCCAATGAAGCC
HDAC1 Y24F for: CGGGGATGTTGGAAATTACTATTTCGGACAAGGCCACCCAATGAAGCC
HDAC1 M30A rev: GGGTGGCCTTGTCCATAATAG
HDAC1M30A for: GGACAAGGCCACCCAGCGAAGCCTCACCGAATC
HDAC1 R34A rev: GGCTTCATTGGGTGGCCTTGTCC
HDAC1 R34A for: GGCCACCCAATGAAGCCTCACGCAATCCGCATGACTCATAATTTGCTG
HDAC1 R34K for: GGCCAC CCAATGAAGCCTCACAAGATCCGCATGACTCATAATTTGCTG
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HDAC1 I35A rev: CGGTGAGGCTTCATTGGGTGG
HDAC1 I35A for: CCCAATGAAGCCTCACCGAGCCCGCATGACTCATAATTTGCTGC
HDAC1 R36A for: CCCAATGAAGCCTCACCGAATCGCCATGACTCATAATTTGCTGC
HDAC1 R36K for: CCCAATGAAGCCTCACCGAATCAAAATGACTCATAATTTGCTGC
HDAC1 S113A rev: CAACTGACAGAACTCAAACAGGCC
HDAC1 S113A for: GGCCTGTTTGAGTTCTGTCAGTTGGCAACTGGTGGTTCTGTGGC
HDAC1 L139A rev: GCCCCCAGCCCAATTCACAGCG
HDAC1 L139A for: GGGCTGGGGGCGCGCACCATGCAAAGAAGTCCGAGGC
HDAC1 C151A rev: GAAGCCAGATGCCTCGGACTTC
HDAC1 C151A for: GTCCGAGGCATCTGGCTTCGCTTACGTCAATGATATC
HDAC1 C151S for: GTCCGAGGCATCTGGCTTCTCTTACGTCAATGATATC
HDAC1 Y303A rev: CCACCGCCTCCCAGCATCAGC
HDAC1 Y303A for: GGGAGGCGGTGGGCTCACCATTCGTAACGTTGCCCGG
HDAC1 Y303F for: GGGAGGCGGTGGTTTCACCATTCGTAACGTTGCCCGG
2.5.3: Polymerase Chain Reaction (PCR)
Two-step (touchdown PCR program) PCR was used to generate PCR inserts with the
mutagenic primers described in section 2.5.2. A typical reaction mixture contained the following
reagents: water (30 µL), DMSO (5 µL), 10X Pfu buffer (5 µL of 200 mM Tris, 100 mM (NH4)2SO4,
100 mM KCl, 1% TritonX-100, 20 mM MgSO4, 1 mg/mL BSA, pH 8.8), DNA plasmid template (1
µL of 0.5 µg/µL), forward primer (1 μL of 25 µM), reverse primer (1 μL of 25 µM), and dNTPs
(2µL of 10 mM ; 2.5mM of each base). PCR reaction mixtures were mixed thoroughly by
pipetting and then heated in a thermocycler (Eppendorf Mastercycler Gradient) for 1 minute at 95
°C and 2 µL Pfu enzyme was added. After addition of the enzyme, initial 10 cycles of the
touchdown program were run as follows: 1 minute 95 °C, 1 minute annealing, 2 minutes
elongation at 72°C. The initial and final annealing temperatures in the 10 cycles were 60 °C and
50 °C respectively with lowering of the temperature by 1 °C per cycle. After another 25 cycles at
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the final annealing temperature of 50 °C, the PCR cycles ended with a 10 minute elongation
period at 72 °C before cooling to 4 °C. DNA products were purified by gel electrophoresis as
described below in section 2.5.4.
The second step PCR was similarly run to create the full length HDAC1-FLAG mutant insert
for homologous recombination using 5 µL of gel purified PCR1 products to replace the DNA
template and the volume of water adjusted to final 50 µL total volume. PCR2 products were
similarly gel purified (section 2.5.4).
2.5.4: DNA agarose gel electrophoresis and gel purification
Gel electrophoresis was done using 1% agarose in 1X Tris-Acetate-EDTA buffer (TAE; 40
mM Tris, 20 mM acetic acid, 1mM EDTA, pH 8.8, 0.5 µg/mL ethidium bromide) for 60 minutes at
120V Separated DNA was purified using the QIAgen gel extraction kit (cat # 28704) and used for
homologous recombination (section 2.5.6).
2.5.5: Restriction digest
pBJ5HDAC1[70] was digested with EcoRI and NotI restriction enzymes (both from
Promega). The restriction digest reaction contained, pBH5HDAC1 (50 ng of 1 µL) buffer H (2 µL;
Promega), BSA (1 µL of 0.1 mg/mL), of Not1 and EcoRI (1 µL each) and water (14 µL). The
reaction mixture was incubated for 2 hours at 37 °C with shaking at 250rpm. The DNA was
recovered by gel electrophoresis (section 2.5.4) followed by extraction using the QIAgen gel
extraction kit.
2.5.6: Homologous recombination in KC8 cells
KC8 cells (50 µL section 2.5.10) were mixed with PCR insert (5 µL; section 2.5.3),
restriction-digested DNA (5 µL; section 2.5.5), KCM buffer (10 µL of 0.1M KCl, 30 mM CaCl2, 50
mM MgCl2) and 30 µL water. The mixture was incubated on ice for 20 minutes followed by a 6090 second heat shock at 42 °C. The cells were then cooled on ice for 2 minutes, before 500 µL of
LB medium (1% peptone, 0.5% yeast extract and 1% NaCl) was added. Cells were incubated for
90 minutes at 37 °C with shaking at 250 rpm. Cells were collected by spinning at 13200 rpm for
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10 minutes and all but 100 µL of the supernatant was removed. The remaining media was used
to resuspend the cell pellet followed by plating on 20 µg/mL kanamycin (to select for KC8) and
50 µg/mL ampicillin LB agar plates (to select for pBJ5HDAC1). The cells were grown overnight at
37 °C. The DNA from individual colonies was mini-prepped as described in section 2.5.8 and
sequenced by the University of Michigan DNA sequencing core.
2.5.7: Bacterial plasmid transformation
Wild type pBJ5HDAC1-Flag or mutant expression plasmids were transformed into
chemocompetent DH5α E. coli (section 2.5.9). DH5α competent cells (100 µL) were thawed on
ice and 1 µL plasmid DNA was added and mixed. Next, the solution was incubated for 20
minutes on ice and heat-shock treated for 60-90 seconds at 42 °C. The cells were quickly
transferred into ice for 2 minutes, after which 0.5 mL of LB media was added. The cells were
grown for 1 hour at 37 °C with shaking at 250 rpm. Cells were collected by spinning at 13000 rpm
for 10 minutes and all but 100 µL of the supernatant removed by aspiration. The cell pellet was
resuspended into the remaining 100 µL and plated on LB agar plates containing 50 µg/mL
ampicillin. Plated cells were grown overnight at 37 °C.
2.5.8: Plasmid mini and midi-preps
One colony of DH5α cells expressing wild type pBJ5HDAC1-Flag or mutant expression
plasmids (section 2.5.7) or KC8 cells containing a new clone (section 2.5.6) was inoculated into
5 mL (mini-prep) or 100 mL (midi-prep) LB containing 50 µg/mL ampicillin. The culture was
grown overnight at 37 °C at 250 rpm. Cells were recovered by spinning at 13200 rpm for 10
minutes at 4 °C. The supernatant was removed by aspiration and the cell pellet was
resuspended into 300 µL (mini-prep) or 4 mL (midi-prep) cold P1 buffer (50 mM Tris-Cl, pH 8.0,
10 mM EDTA, 100 μg/mL RNAse A). Room temperature 300 µL (mini-prep) or 4mL (midi-prep)
P2 buffer (200 mM sodium hydroxide, 1% SDS) was added and mixed by inversion prior to
incubation for 5 minutes at room temperature with constant gentle mixing. Cold P3 buffer (300
µL for mini-prep or 4 mL for midi-prep of 3.0 M potassium acetate, pH 5.5) was added, mixed by
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inversion, and incubated on ice for 15 minutes (inversion every 5 minutes). The cell debris was
removed by spinning at 13200 rpm for 10 minutes and the supernatant was loaded on a QIAgen
column (midi-prep; needed for mammalian transfection) or a pre-chilled tube containing 540 μL
of isopropanol. Midi-prep DNA was prepared as per the Qiagen protocol. The mini-prep was
incubated on ice for 5 minutes after which the DNA was collected by spinning at 13200 rpm for
10 minutes, the supernatant was removed by aspiration, and the DNA was redissolved in 20 μL
water and stored at -20 °C.
2.5.9: Preparation of chemocompetent DH5α Blue E. coli
DH5α E. coli was made chemocompetent by calcium chloride treatment to allow for plasmid
uptake or transformation for subsequent replication to produce large amounts of plasmid. A
single colony of DH5α was inoculated into 25 mL LB and grown overnight at 37 °C with shaking
at 250 rpm. On day 2, 4 mL of the overnight culture was diluted into 400 mL LB and similarly
grown until OD600=0.375. Portions of the growth culture (50 mL) were transferred into 50 mL
pre-chilled centrifuge tubes and cooled on ice for 10 minutes, followed by spinning at 4000 rpm,
for 10 minutes at 4 °C. The liquid supernatants were removed via aspiration and the cell pellets
were washed 3 times with 10 mL cold CaCl2 solution (60 mM CaCl2, 10 mM PIPES, and 15% v/v
glycerol). After the last wash, the cell pellets were resuspended in 2 mL of CaCl2, split into 100
µL aliquots, and stored at -80 °C until use.
2.5.10: Preparation of KC8 competent cells
KC8 cells were obtained from the Finley lab (Wayne State University). An overnight culture
(5 mL) grown at 37 °C with 250 rpm shaking was diluted into 500mL LB media. The cells were
further grown for about 3-4 hours at the same growth conditions until OD600 reached about 0.5.
Cells were recovered by spinning at 3500 rpm for 15 minutes at 4 °C and the LB was poured
out. Cells were resuspended into 25 mL cold LBSB (LB diluted with HCl to pH 6.1, 10% (w/v)
PEG 3400, 5% (v/v) DMSO, 10% glycerol, 10 mM MgCl2, 10 mM MgSO4) and incubated on ice
for 10 minutes. The cells were split into 250 µL aliquots and stored at -80 °C until use.
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2.5.11: Mammalian cell growth and storage
TA-g Jurkats cells [77] were grown in RPMI-1640 media (GIBCO) supplemented with 10%
FBS (GIBCO) and 1% antibiotic-antimycotic (GIBCO). Cells were grown at 37 °C in 5% CO2 to a
maximum confluency of 1 million cells/mL. Cells were passaged each day and cell count was
determined using Tryptan blue stain (GIBCO) and a hemocytometer. For storage, approximately
10 million cells were harvested by spinning at 1000 rpm at 4 °C for 5 minutes and the growth
medium was removed by aspiration. The cell pellet was re-suspended in 1 mL RPMI -1640
medium containing 5% glycerol. Cells were transferred into cryovials, which were wrapped in
styroform and slowly frozen, first at -20 °C overnight, and then transferred to -80°C for a day
before moving them to liquid nitrogen.
2.5.12: DNA transfection
Plasmid DNA purified using the QIAgen kit (see section 2.5.8, 20 µg, pBJ5HDAC1-Flag or
mutants) was separately transiently transfected into 40 X 106 TA-g Jurkat cells by
electroporation using 4 mM electroporation cuvettes. Briefly, cells were harvested by spinning at
1000 rpm for 5 minutes at 4 °C. The supernatant was removed by aspiration and the cell pellet
was resuspended in 20 mL RPMI medium without FBS and phenol red pH indicator (GIBCO)
followed by spinning and medium removal. The cell pellet was resuspended in 800 µL RPMI
media (no pH indicator or FBS) and transferred into eppendorf tubes. Plasmid DNA was added,
mixed, set at room temperature for 10 minutes, and transferred into BTX 4 mM gap
electroporation cuvettes (Fischer Biotech). Electroporation was carried out using a BTX Electro
cell manipulator 630. For every 10 X 106 cells in 200 µL media the following settings were used:
S-250 V, T-500V/capacitance and resistance, C-800 µF and R-129 Ohms. The µF output was
varied depending on the quantity of cells as follows; 10 X 106 cells: 800 µF, 20 X 106 cells: 1600
µF, 30 X 106 cells: 2100 µF and 40 X 106: 2800 µF. The pulse length (1/e) was around 35 msec
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for optimal electroporation and the presence of a frothy precipitate due to dead cells is normal.
Electroporated cells were set at room temperature for 10 minutes, transferred to 10 mL of warm
(37 °C) RPMI-1640 (with 10% FBS and 1% antibiotic) for every 10 X 106 cells and grown for 48
hours as described in section 2.5.11. The cells were harvested by spinning at 1000 rpm for 5
minutes at 4 °C and washed with 1 mL of PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4,
1.4 mM KH2PO4 pH 7.3). PBS was removed by spinning at 1000 rpm, for 5 minutes at 4 °C and
the cells were used immediately or stored at -80 ˚C until use.
2.5.13: Immunoprecipitation
TA-g Jurkat (40 X 106 ) cells expressing HDAC1-FLAG wild type or mutant proteins were
lysed in cold Jurkat lysis buffer (50 mM Tris pH 8, 150 mM NaCl, 10% (v/v) glycerol, 0.5 % (v/v)
Triton X-100) containing 1X protease inhibitor cocktail set V (Calbiochem). Briefly, the cells were
lysed by pipetting in 0.5 mL of cold JLB buffer for every 20 X106 cells and incubating with
rotation at 4 °C for 30 minutes. The soluble fraction was separated from cell debris by spinning
at 15000 rpm for 10 minutes at 4 °C.

Anti-Flag agarose beads (10 µL of bead slurry, Sigma)

were used to immunoprecipitate HDAC1-Flag wild type or mutant proteins in 1 mL cold TBS
buffer (50 mM Tris HCL, with 150 mM NaCl, pH 7.4). The beads were prepared by washing
three times with 0.5 mL TBS followed by spinning at 1000 rpm for 5 minutes at 4 °C, with buffer
removal in between washes.

Immunoprecipitation was carried out at 4 °C for 2 hours with

rotation by incubating 400 µL lysates with the washed beads. Immunoprecipitated proteins were
harvested by spinning at 3200 rpm for 5 minutes at 4 °C. Immunoprecipitates were split in half:
half was used for gel analysis (section 2.5.14) and the other half for HDAC assays (section
2.5.15). For gel analysis, FLAG-fusion proteins were eluted from the agarose bead by adding 40
µL of 0.1M glycine HCl, pH 3.5, and incubating for 5 minutes at 4 °C with gentle shaking. The
supernatant containing the FLAG-fusion protein was recovered by spinning at 3200 rpm for 5
minutes at 4 °C. The supernatant was neutralized by transferred into a clean tube containing
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10µL 0.5 M Tris HCl, pH 7.4, and 1.5 mM NaCl. The eluted protein was used immediately in
SDS-PAGE experiments (section 2.5.14)
2.5.14: SDS-PAGE
β-mercaptoethanol (1 µL) and 5XSDS loading buffer (10 µL of 50 mM Tris-Cl pH 6.8, 100
mM dithiothreitol, 2% (w/v) SDS electrophoresis grade, 0.1% bromophenol blue, 10% (v/v)
glycerol)) was added for every 40 µL immunoprecipated FLAG-fusion proteins. Each solution
was incubated at room temperature for 5 minutes. The mixtures were heat at 95 °C for 1 minute
and quickly cooled on ice prior to loading onto the gel. When using lysates, 10 µL lysates was
added to 10 µL SDS loading buffer with 10% β-mercaptoethanol. The separating layer of the
SDS-PAGE gel was prepared to contain 10% 37:1 acrylamide/ bisacrylamide (Acros) by mixing
1 mL 4X Tris/SDS buffer (0.4% SDS, 1.5 M Tris, 0.24 M HCl; pH 8.8), 1.96 mL water, 1 mL 40%
37:1 acrylamide/bisacrylamide, 40 µL ammonium persulfate and 2 µL 10% TEMED (N, N, N’,
N’-tetramethylthylenediamine; Acros). The mixture was mixed thoroughly and immediately
poured into a BioRad mini-Protean tetra cell casting module. The surface of the gel was covered
with methanol and allowed to polymerize. The stacking layer was prepared by mixing 1.24 mL
water, 250 µL 40% 37:1 acrylamide/bisacrylamide, 500 µL 4X Tris/SDS buffer (0.4% SDS, 1.5
M Tris, 0.24 M HCl; pH 6.8), 10 µL of 10% ammonium persulfate and 1 µL TEMED. Methanol
was removed from the polymerized separating layer and the stacking layer mixture was poured
followed by the addition of a comb; the layer was allowed to polymerize. The gels were inserted
into the BioRad (Protean III) gel apparatus, which was filled with SDS running buffer (0.1%
SDS, 25 mM Tris, 250 mM glycine; pH 8.3). The gel wells were loaded with samples and run at
200 V for 60 minutes.
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2.5.15: Western blot and co-immunoprecipitation
To probe protein bands with anti-Flag (Sigma), anti-mSin3A (Santa Cruz) or anti-RbAp48
(Sigma) antibodies, the proteins in the SDS gel were transferred onto a polyvinylidene (PVDF)
membrane (Millipore Immobilon-P, 0.45 micron).

The membrane was activated for protein

transfer by soaking in methanol. Both the membrane and gel were assembled between filter
paper and padding and transferred into the BioRad gel electrophoresis chamber containing an
ice cooling tray. The chamber was filled with CAPS/methanol transfer buffer prepared by mixing
100 mL 10X CAPS (0.1 M CAPS, pH adjusted to 10.5 with 10 M NaOH) and 800 mL distilled
water. The transfer was run for 1 hour at 90 Volts. The membrane was carefully removed and
air dried to ensure proteins were bound. The membrane was wet in methanol and blocked
overnight with 10% low fat dry milk in 10 mL of PBST (PBS with 0.1% Tween). After blocking,
blocking solution was removed and the membrane was washed three times with 5 mL of PBST
to remove unbound milk. The membrane was probed with primary antibody (1:10,000 dilution in
10% low fat dry milk and PBST, containing 0.002% sodium azide preservative) by rocking for 2
hours. After 2 hours, the membrane was washed 3 times with 5 mL PBST to remove unbound
antibody. The membrane was coated with a fluorescently labeled secondary anti-mouse (1:
5000, Alexa Fluor 647; Life Technologies) or anti-rabbit (1:3000, Alexa Fluor 647; Life
Technologies) antibody solutions in PBST containing 10% low fat dry milk for 1 hour. The
antibody solution was removed and the membrane was washed three times with 5 mL PBST to
remove unbound antibody.

Proteins were visualized using a Typhoon 9210 variable mode

imager (Amersham Biosciences) by measuring the fluorescence at 670 nM.
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2.5.16: HDAC activity assay
The Fluor de LysTM fluorescence activity assay (Biomol) was used to determine HDAC
activity. Approximately 20 µg total protein was immunoprecipitated as described in section
2.5.13 and used in this assay. The bead-bound HDAC immunoprecipitates were incubated with
25 µL HDAC assay buffer (50 mM Tris/Cl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2) and
25 µL substrate (100 µM; Prod. No. BML-KI104) at 37 ˚C for 45 min with shaking (900 rpm).
Then, 50 µL 20X developer (Prod. No. BML-KI105) was added and incubated for 5 min at 37 °C.
The reaction mixture was transferred into a white microplate (Prod. No. BML-K571) and the
fluorescence signal was measured using the GENios plus plate-reader fluorimeter (Tecan) with
an excitation wavelength of 360 nm and emission of 465 nm wavelength. The fluorescence
signal for each mutant was normalized to the wild type (set at 100%) and standard errors from
at least four independent trials are provided in the appendix (Table A.1 and A.2).
2.5.17: Acetate competition assay
To perform the acetate competition assay, the activity of mutant proteins was determined
using the Fluor de LysTM kit with some modifications. Immunoprecipitation was done as
described in section 2.5.13 and then split into 5 equal aliquots. Each aliquot was incubated with
25 µL HDAC assay buffer containing 0-200 mM sodium acetate (Table A.3-A.9) for 15 minutes
at 37 ˚C with shaking. The deacetylase activity was determined as described in section 2.5.16.
The percent deacetylase activity was determined by normalizing the fluorescence signal at each
concentration to the no acetate control for each mutant (no acetate=100%) and standard errors
from at least four independent trials are shown in the appendix (Table A.3-A.9).
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Chapter 3
Introduction
3.1: Efforts towards the first HDAC1-‘bump hole’ inhibitor pair
(Portions of the text in this chapter were reprinted or adapted with permission from Weerasighe
S.V., Wambua M., and Pflum M.K (2010) A Histone dependent screen in Yeast, Bioorg. Med.
Chem., 18, 7586-7592.)
Overexpression of one or more histone deacetylase (HDAC) proteins is observed in many
cancers (Chapert 1, section 1.5). Unfortunately, it is still unclear which HDAC isoform(s) are
involved in cancer formation. Understanding the involvement of each HDAC isoform in cancer is
critical to aid in the design of isoform selective inhibitors. Use of HDAC inhibitors has been
shown to reduce malignancies but, unfortunately, most HDAC inhibitors interact with all or most
of the eleven known human isoforms. With FDA approval of the HDAC inhibitors FK-228 and
suberoylanilide hydroxamic acid (SAHA) for the treatment of cutaneous T-cell lymphomas, the
discovery of more HDAC inhibitors is a promising area of cancer research. Consequently,
various HDAC inhibitors are in different phases of clinical trials to treat cancer [62].
HDAC1 is an attractive target for anti-cancer drugs (see chapter 1, section 1.5). HDAC1
regulates the cell cycle, cellular proliferation and development, key events that can lead to
cancer development if aberrant. HDAC1-deficient mouse embryonic stem cells deciphered the
dominant role of HDAC1 in growth, development and cellular proliferation [54]. Specifically,
deletion of HDAC1 resulted in embryonic lethality at E10.5 in mice, which was attributed to
severe defects in proliferation and retarded growth [54]. The observed reduction in proliferation
correlated with the upregulation of cyclin-dependent kinase inhibitors p21 and p27 and an
overall reduction in deacetylase activity. Importantly, loss of HDAC1 led to induction of HDAC2
and 3, but both isoforms were unable to compensate for the HDAC1 deletion, suggesting that
HDAC1 plays a critical role in development and cellular proliferation by regulating cell cycle
check-point genes. Further, mouse fibroblast cells lacking HDAC1 are anti-proliferative and
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exhibit G1-cell cycle arrest accompanied by the up-regulation of CDK inhibitors p21 and p53
[56]. In addition, B-cell development was blocked following HDAC1 deletion, which was
accompanied by G1-cell cycle arrest and induction of apoptosis. Combined, these studies
showed that HDAC1 regulates G1-S phase transition in the cell cycle by repressing the
expression of p21 and p53. Aberrant cell cycle regulation and proliferation are hallmarks of
cancer formation, and HDAC1 is thus a potential target for Dace drug design. Currently, no
HDAC1 selective inhibitor is yet available.
To achieve better therapies for cancer treatment, it is important to understand the individual
functions of each HDAC isoform, which will aid in design of isoform selective HDAC inhibitors.
As a first step towards this goal, studies in this chapter are focused on HDAC1. Conventional
genetic strategies have revealed that HDAC1 regulates cell cycle, tissue differentiation and
development [54, 55]. In addition, the use of mouse knock-out models and siRNA silencing has
been useful in understanding the individual functions of other HDAC proteins (see section 3.1).
As an alternative to genetic methods, small molecules offer a temporal, time-dependent, and
reversible control of gene silencing which is unattainable with genetic methods.

Studies

outlined here examine the bump-hole approach, a combination of genetic manipulations and
small molecules incubation, to understand the involvement of HDAC1 in cancer formation.
Understanding the role of HDAC1 in cancer formation will aid in developing better cancer
therapies targeting HDACs.
3.1.2: The utility of a bump-hole pair:
3.1.2.1: The kinase bump-hole
The bump-hole strategy has been used successfully to design allele-specific inhibitors to
probe kinase signaling (Figure 3.1) [78]. Protein kinases have highly conserved domains,
making the design of selective highly specific inhibitors very difficult. Chemical biology has
allowed the design of allele specific kinases to probe kinase signaling for individual kinases.
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Figure 25: The kinase bump-hole to probe kinase signaling [78]. A) Kinase catalytic domains
are highly conserved (red ovals) and therefore the majority of potent kinase inhibitors (red oval)
would block the activity of closely related kinase and their pathways regulated by kinase activity.
Gel analysis for phosphorylated proteins shows completed blockage of kinase activity by potent
inhibitors shown at the bottom.B). Src kinase is engineered to contain a hole that is uniquely
complementary to a small molecule inhibitor, allowing for selective inhibition of one kinase as
opposed to all kinases. The panel shows gel analysis for phosphorylated proteins with selective
blockage of an engineered kinase activity by the modified inhibitor (Pink ovals represent kinase
substrates; Y and S represent tyrosine and serine respectively). Reproduced with permission
from Curr. Bio.,1998, 8: 257-266.
To create a bump-hole, the kinase protein is mutated to contain a hole and a small
molecule inhibitor is modified to contain a bump that is complementary to the hole. A kinase
bump-hole study focused on two structurally related Src kinases, v-Src and Fyn, which display
85 % sequence homology in their catalytic domains. A functionally silent threonine to
isolecucine mutation for the kinase of interest was created in the active site to give rise to a
unique pocket that could accommodate a bumped adenosine mimic inhibitor [78]. Importantly,
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the ATP mimic inhibited the engineered kinase more potently than the wild type or other non-Src
family kinases (>100-fold selectivity). Treating NIH3T3 fibroblasts transfected with the
engineered v-Src kinase with the adenosine-mimic inhibitor blocked tyrosine phosphorylation;
this phenotype was not observed with the wild type kinase. To further demonstrate selective
inhibition of the engineered v-Src kinase variants by a bumped ATP mimic, mammalian cellular
transformation by the Rous sarcoma virus, which is dependent on v-Src activation, was
determined. NIH3T3 cells expressing engineered v-Src, but not the wild type v-Src, exhibited flat
cell morphology upon treatment with the adenosine mimic inhibitor; this morphology is attributed
to reversal of cellular transformation. Importantly, the engineered Fyn kinase with a mutation at
a similar position was selectively inhibited by the same adenosine-mimic inhibitor,
demonstrating that the bump-hole strategy can be extended to other kinase families.
Other such bump-hole studies have been done in recent years. For instance, mutation of
the highly conserved phenylalanine 338 to glycine in the active site of the cyclin-dependent
kinase Cdc28 (CDK1) creates a unique ATP-mimic inhibitor binding pocket in [79]. The smaller
glycine residue acts as a gate keeper to allow for bulkier ATP analogs to access the active site
and sensitizes Cdc28 to specific inhibitors. The allele-sensitive Cdc28 was used to understand
the biology of budding yeast. Specifically, inhibiting the mutant Cdc28, but not the wild type
enzyme, in vivo caused pre-mitotic cell cycle arrest and thereby facilitated a functional
characterization of this kinase [79].

A different study focused on the Toxoplasma gondii

calcium-dependent protein kinase 1 (TgCDPK1) [80]. Unlike other protein kinases in T. gondii,
the presence of a glycine residue at the gate-keeper position renders TgCDPK1 sensitive to
pyrazolopyrimidine-derived inhibitors and mutating the glycine to a methionine residue leads to
insensitivity [80]. Specific inhibition of TgCDPK1 revealed that TgCDPK1 controls calciumdependent secretion of specialized organelles, the micronemes, which blocks parasite motility,
host-cell invasion and egress [80]. These observations were recapitulated using conditional
knock-out models as well as expression of a resistant mutant kinase or other T. gondii protein
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kinases [80]. A recent development was reported in 2012 [81]. In this study, the methionine
residue at the gatekeeper position of calcium-dependent protein kinase 3 (TgCDPK3) was
mutated to glycine and thereby rendered sensitive to a pyrazolopyrimidine-derivative inhibitor
(PPI). Inhibiting the allele-specific TgCDPK3 with PPI derivatives demonstrated that TgCDP3 is
essential for parasite egress but not host invasion or motility [81]. These combined studies
demonstrate the successful use of allele-specific kinases along with enlarged inhibitor
compounds with increased potencies for functional characterization of closely related protein
kinases in T. gondii.
3.1.2.2: HDAC1-inhibitor bump-hole
Allele-specific kinase inhibitor pairs have been used to understand kinase signaling and
biological relevance (section 3.1.2.1). Similar to kinases, an allele specific HDAC1-inhibitor pair
would be useful for understanding HDAC1 biology.

Importantly, the bump-hole is a great

alternative to the development of isoform selective HDAC inhibitors, in order to explore HDAC1
biology.
A functional characterization of the role of HDAC1 in cancer can be conducted using the
bump-hole strategy in cell based assays (Figure 3.2). Our proposition is that HDAC inhibitors
(HDACi) can be modified to contain a steric bump which is accommodated by a mutant HDAC1
with a complementary hole (Figure 3.2A). Importantly, the modified HDACi must be excluded
from binding the wild type HDAC1 (Figure 3.2B). The HDAC1-inhibitor bump-hole pair can be
used to study the expression profiles of cancer related genes influenced by HDAC1.
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Figure 26: A cartoon showing the rationale of the bump-hole approach. (A) Wild-type
HDAC1 is mutated to contain a hole. A small molecule inhibitor is modified to contain a bump.
The bumped inhibitor fits into the hole of the mutant but not the wild type. B) In a cellular
context, the modified inhibitor analogue inhibits the mutant HDAC1 but not the wild type or the
other HDAC isoforms.
The HDAC1-inhibitor bump-hole pair is summarized in Figure 3.3. The wild type HDAC1 is
knocked down using siRNA (Figure 3.3B). The active HDAC1 mutant containing a ‘hole’ is
expressed (Figure 3.3C) at the same time that the wild type HDAC1 is knocked down by siRNA.
A small molecule inhibitor analogue is used to inhibit the mutant but not the other HDAC
isoforms (Figure 3.3D). The expression profile of cancer related genes influenced by HDAC1
alone but not the other HDAC isoforms is determined by comparing the results from panels C
and D. Further, inhibiting all HDAC isoforms can be done using a pan-HDAC inhibitor (Figure
3.3E or F) and comparative studies for expression profiles gives the cancer related genes
influenced by all the other HDAC isoforms but not HDAC1.
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Figure 27: Dissecting the individual functions of HDAC1 using the bump-hole strategy.
siRNA is used to knock-out HDAC1 (B). The engineered HDAC1 mutant is expressed (C).
Cells are treated with a bumped-inhibitor analogue which selectively inhibits the mutant
HDAC1 but not the other HDAC isoforms (D). Pan-HDAC inhibitor is introduced to inhibit all
the HDACs (E and F).
3.1.2.3: Approaches to obtain an HDAC1-inhibitor bump-hole pair
Unfortunately, the creation of active HDAC1 mutants for use in the bump-hole has been
challenging (Chapter 2). With over 80 HDAC1 mutants characterized so far in the Pflum lab,
only the E98A mutant was catalytically active, making it challenging to proceed with the bumphole project (Chapter 2, figure 2.7). As an alternative, we envisioned creating combinations of
several point mutations, which might restore catalytic activity. This approach is only feasible in
the more tractable yeast system, which is easier to manipulate. HDAC1 is homologous to the
yeast Rpd3 protein and therefore active mutations in Rpd3 are often conserved in HDAC1. Our
second approach for creating a bump-hole pair was to screen the active HDAC1E98A protein
against libraries of SAHA analog compounds produced in the Pflum lab. Both of these strategies
are discussed in this chapter.
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3.2: Results
3.2.1: Development of an HDAC dependent yeast gene reporter screen
Rpd3, the yeast histone deacetylase shares 60% sequence identity with its human HDAC1
homologs and is a component of the Sin3 corepressor complex [82]. However, unlike HDAC1,
which regulates growth, development, cell cycle and proliferation, the Rpd3-Sin3 repressor
complex negatively regulates genes involved in potassium transport, meiosis, phospholipid
metabolism, phosphate metabolism and cell-type specificity [82]. The high sequence similarity
between Rpd3 and class I HDACs makes Rpd3 an ideal model to study class 1 proteins in the
more tractable yeast system. Therefore, it is probable that active mutants obtained in Rpd3 will
be transferable to human HDAC1. A major challenge, however, is to have a functional screen
for selecting active mutants from a large mutant library. This issue necessitated the
development of a yeast reporter screen dependent on Rpd3 activity.
A high throughput screen capable of testing a library of Rpd3 mutants for activity is ideal.
The current fluorimetric assay used in chapter 2 is sensitive and is the most widely used in the
field. The assay is dependent on fluorophore-labeled peptide substrate and has been widely
used for mutant and inhibitor studies. In addition, several other assays developed in the past
have relied on radio-labeled acetylated histones or peptide substrates [7]. Unfortunately, the
HDAC is usually sourced from HeLa nuclear extracts and is therefore disadvantageous in
inhibitor screens because the inhibition profile is a reflection of the overall HDAC activity and
cannot be attributed to a specific HDAC isoform.

Efforts to purify individual isoforms for

selectivity studies are hindered by the fact that bacterially expressed HDACs are inactive,
presumably due to the lack of associated proteins, which are needed for catalytic activity. As an
alternative, baculovirus-expressed HDAC sources, which have shown 70% reduction in
enzymatic activities, have also has been explored but this loss in deacetylase activity limits their
use. In addition, these assays are cost prohibitive and would therefore not be ideal for a high
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throughput, library screening. The development of a high throughput cost effective screening
assay will be ideal for identification of active mutants and inhibitor screen. Further, the histone
deacetylase screen developed in Rpd3 is dependent on native substrates unlike the commercial
kits.
3.2.1.1: Design of a yeast gene reporter screen
The Rpd3 dependent yeast gene reporter screen utilizes the LACZ gene product βgalactosidase, which cleaves 5-Bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal), giving
a blue color, or 2-Nitrophenyl β-D-galactopyranoside (ONPG), giving a yellow color (Figure
3.4A). These color changes can be monitored to assess HDAC activity. Rpd3 is expressed as a
LexA fusion protein; LexA recruits Rpd3 to the LexA DNA binding promoter region upstream of
the LACZ gene. The yeast FT5ΔRpd3 strain, with a deletion of the endogenous Rpd3, is
transformed with reporter plasmid and the Rpd3 expression construct. Transformation of the
LACZ reporter alone gives basal LACZ expression under a constitutively active promoter and
results into a colored cell (Figure 3.4A). Expression of Rpd3-LexA together with the reporter
results in recruitment of Rpd3 to the LexA DNA binding region in the promoter region. Rpd3 will
deacetylate nucleosomal DNA turning off LACZ gene transcription. Lack of β-galactosidase
activity then yields a white cell (Figure 3.4.B). A catalytically inactive mutation in Rpd3 or
inhibition of the wild type Rpd3 leaves DNA acetylated, LACZ gene transcription is turned on
and the cells are colored (Figure 3.4C). The LACZ gene reporter can screen Rpd3 mutants for
activity or inhibitor selectivity.

60

Figure 28: Schematic diagram of yeast based LACZ gene reporter screen. (A) When the
LACZ reporter is transformed alone, the LACZ gene under the control of a constitutively active
promoter, expresses β-galactosidase (β-gal) which hydrolyzes the 5-Bromo-4-chloro-3-indolylβ-D-galactopyranoside substrate (X-Gal), resulting a blue color, or the 2-Nitrophenyl β-Dgalactopyranoside substrate (ONPG), resulting in a yellow color. The color changes can be
monitored to assess the HDAC activity. (B) When the catalytically active Rpd3 LexA fusion is
expressed and recruited to the reporter, the nucleosomal DNA will be deacetylated and
inaccessible to the transcription machinery, causing LACZ gene transcription to be turned off
and the cells to be white. (C) A catalytically inactive Rpd3 mutant fails to inhibit LACZ
expression and results in blue and yellow cells. Inhibiting active Rpd3 mutants or wild type
with a small molecule will give similar results.
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3.2.1.2: Validation of the Rpd3-dependent screen using a qualitative X-Gal agar format
To determine if the yeast screen is suitable for mutant and inhibitor screening, the assay
was developed and optimized. The LACZ reporter plasmid, pJK1621 (obtained from Prof.
Struhl), was transformed into the FT5 Δrpd3::HIS3 yeast strain (wherein the endogenous rpd3 is
deleted) with or without the Rpd3-LexA fusion plasmid (cloned in our lab, see section 3.5.2) [69].
The β-galactosidase activity was monitored using X-Gal. The X-Gal assay is a qualitative agar
layout that allows for an initial validation of the screen. The LACZ reporter alone strain showed
basal β-galactosidase activity and a resultant blue colored yeast cell (Figure 3.5A).
Transforming the LACZ reporter together with Rpd3 resulted in low β-galactosidase and a white
colored cell (Figure 3.5C), suggesting that Rpd3 represses LACZ gene expression.

As

expected, the catalytically inactive Rpd3H150A151A mutant showed low β-galactosidase levels
that were comparable to the reporter alone and gave a blue colored cell (Figure 3.5 D).
Inhibiting Rpd3 with trichostatin A (TSA) resulted in high levels of β-galactosidase and a blue
color as expected (Figure 3.5F). Endogenous HDAC activity with the LACZ reporter alone is
negligible as TSA treatment gave similar β-galactosidase activities (Figure 3.5B). The solid XGal screen is therefore ideal for mutant and inhibitor screens.
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Figure 29: The Rpd3-dependent gene reporter screen (data obtained by Sujith Weerasighe)
[83]. LACZ reporter plasmid, pJK1621, was transformed with or without wild type Rpd3 or
catalytically inactive Rpd3 mutant as LexA-FLAG fusions, into FT5 Δrpd3::HIS yeast strain.
Transformed cells were grown with or without TSA for 48 h in 96 well format and were overlaid with
X-Gal substrate. The β-galactosidase activity was observed qualitatively by blue color formation
after 3h of X-Gal incubation. Columns represent (A) LacZ reporter alone, (B) LacZ reporter + TSA
100 µM, (C) LacZ reporter + Wild type Rpd3-LexA, (D) LacZ reporter + Rpd3-LexA mutant, (E)
LacZ reporter + wt Rpd3-LexA +100 µM TSA and (F) LacZ reporter + Rpd3-LexA mutant + 100 µM
TSA. The experiments were carried out in triplicate (rows 1, 2 and 3). Reproduced with permission
from Bioorg. & Med. Chem., 2010, 18, 7586-7592.
3.2.1.3: The LACZ gene reporter assay can be quantified
A quantification of Rpd3 dependent repression of β-galactosidase activity was further
determined using ONPG as a substrate. The liquid format makes it possible to quantify the
amount of Rpd3 deacetylase activity by measuring the absorbance of ONPG hydrolysis product
at 420 nm. The LACZ reporter plasmid alone gave high levels (2.4-fold compared to wild type
which was normalized to 1) of β-galactosidase and is consisted with X-Gal results (Figure 3.6,
column 1 reflecting basal LACZ expression levels from a constitutive promoter. Rpd3-LexA,
together with the LACZ reporter resulted in loss in β-galactosidase activity, suggesting that
Rpd3 repressed LACZ expression (Figure 3.6, column 3). However, this suppression was
reversed by TSA treatment and resulted in 2.5-fold increase in β-galactosidase activity. The
inactive Rpd3 H150AH151A mutant was unable to suppress LACZ expression and resulted in a
2.4-fold increase in β-galactosidase activity (Figure 3.6, column 5). Importantly, the LACZ
reporter alone gave similar β-galactosidase activity with and without TSA, suggesting that
endogenous HDAC activity is negligible, as previously observed with the X-GAL assay (Figure
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3.6 lane B). The combined results indicate that both the qualitative X-Gal and quantitative
ONPG assays are dependent on the activity of Rpd3-LexA, making the yeast screen ideal for
Mean

identifying active mutants as well as inhibitor screen.
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Figure 30: Quantitative inhibition of Rpd3 activity; data obtained by Sujith Weerasighe
[83]. LacZ reporter plasmid, pJK1621, was transformed with or without wild type Rpd3 or
catalytically inactive Rpd3 mutant as LexA-FLAG fusions into FT5 Δrpd3::HIS yeast strain.
Transformed cells were grown with or without TSA for 6h at 30 °C and β-galactosidase activity
was measured quantitatively using ONPG and absorbance at OD420. Relative fold change in βgalactosidase activity was calculated with respect to wild type Rpd3 and mean of three trials is
shown with standard error (as error bars). Relative fold changes observed in each trial are
summarized in Appendix B (Table B.1). Reproduced with permission from Biorg. & Med. Chem.,
2010, 18, 7586-7592.
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3.2.1.4: Screening yeast libraries for active mutants
The LACZ gene reporter assay was used to screen a 15,000 member library (see
experimental section 3.5.1 and 3.5.2) previously generated by Sujith Weerasighe (unpublished
work). The amino acids F214, F215, and L281 positions were mutated to create this Rpd3
library. These amino acids are located near the solvent exposed region of the enzyme’s active
site and their contributions to the catalytic activity of Rpd3 has never been reported (F214, F215
and L281, are similar to F204, F505 and F271 in HDAC1 respectively and are located further
from the active site (Chapter 2, figure 2.6). We envisioned that random mutagenesis would
create a combination of mutants that could be active; loss of activity as a result of a mutation of
one amino acid could be compensated for by another amino acid in the same mutant, therefore
increasing the chances of creating an active mutant for the bump-hole approach. In order to
screen the 15,000 mutants for activity using the yeast gene reporter assay as described in
section 3.2.1.1, mutants were transformed into the FT5ΔRpd3::HIS strain cell line together with
the LACZ gene reporter plasmid, pJK1621. Transformed yeast cells were subjected to bluewhite screening as discussed in section 3.5.6. A representative result of the X-Gal blue-white
screen is shown in Fig. 3.7 (white colonies are shown by arrows). The expectation was that
cells containing an active Rpd3 mutant would repress β-gal expression and color change. It was
necessary to do an initial selection screen to identify possible hits for further evaluation using
the quantitative ONPG assay and fluorescence assay. One hundred white colonies were picked
to move forward to further screening.
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Figure 31: LacZ gene reporter screen for active mutants (X-gal overlay assay; Blue-white
screen). Rpd3 mutant expression plasmids were transformed into the FT5ΔRpd3::HIS strain
cell line. Yeast cells were grown for 3 days and overlaid with X-Gal solution and then incubated
for 2 hours. Development of blue color was monitored visually. The arrows show white mutants
that are thought to be ‘active mutants’ from this screen.
3.2.1.5: Quantification of β-galactosidase activity for white mutants identified in X-Gal
screen
The ONPG screen allows for quantification of deacetylase activity for white colonies and is
also a secondary confirmatory assay of the quantitative X-Gal plate assay. To confirm the
deacetylase activities of colonies from the blue-white screen using X-Gal (Section 3.2.1.4),
colonies were retrieved from the agar, re-grown for 2 days in liquid medium and the ONPG
assay was applied as described in experimental section 3.5.7. A representative screen for ten
white colonies (out of the hundred selected) is shown in figure 3.8. The wild type Rpd3
repressed β-galactosidase expression and showed low levels of activity as expected (Figure
3.8, column 1, positive control). The inactive Rpd3H150AH151A double mutant was unable to
repress LACZ expression and resulted into a 4.5-fold increase in β-galactosisade activity
(column 2, negative control). Out of the ten mutants screened in this representative assay,
mutants 3 and 7 showed low β-galactosidase activities (Figure 3.8, columns 3 and 10). The rest
of the mutants showed high β-galactosidase activities (Figures 3.8, columns 1, 2 and 4-9)
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suggesting that these mutants do not repress LACZ expression.

In total, the ONPG assay

validated 60 colonies which were screened for activity using a fluorimetric assay (Section
3.2.1.6).

Figure 32: LacZ gene reporter assay screen for active mutants (ONPG assay). LacZ
reporter plasmid, pJK1621, was transformed with wild type Rpd3 or a catalytically inactive Rpd3
mutant or the Rpd3 library plasmid DNA as LexA-FLAG fusions into the FT5 Δrpd3::HIS yeast
strain. Transformed cell were grown overnight at 30 °C. β-galactosidase activity was measured
quantitatively. Relative fold change in β-galactosidase activity was calculated with respect to
wild type Rpd3 and the mean of two trials is shown (no error bars). Mutants 3 and 10 are
thought to be active mutants. While data from a single trial is shown here, the relative fold
change observed in two independent trials is summarized in Appendix B (Table B.2).
3.2.1.6: HDAC assay for identified mutants
In order to validate the activity of the 60 mutants form the ONPG screen, the commercially
available kit, Fluor-de-Lys (Biomol), was used to confirm HDAC activity (Appendix B.3). A
representative set of results is shown in Figure 3.9. The wild type Rpd3 has high deacetylase
activities (set to 100%) whereas the mutant Rpd3H150AH151A mutant has low deacetylase
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levels (20%) compared to wild type (Figure 3.9). Of the five mutants tested, mutants 3 and 6
maintained high deacetylase activities at 93% and 85% respectively (Figure 3.9, columns 3 and
6). The three other mutants had low deacetylase levels (10-30%) comparable to the
Rpd3H150AH151A control (Figure 3.9, columns 4, 5 and 7). Using the HDAC assay, 19 of the
60 mutants were confirmed as active mutants; these were sequenced to determine the
presence and identification of any mutations.

Figure 33: Representative results from an HDAC assay of active mutants identified using
the LacZ gene reporter screen. Rpd3 wild-type, Rpd3 H150A151A mutants or the validated
mutant(s) were expressed as FLAG-tagged fusion proteins and were immunoprecipitated with
anti-FLAG-agarose resin. The immunoprecipitated protein were used in fluorescence HDAC
assays .The percent activity is compared with that of the wild-type protein (100%). The
deacetylase activities for each trial are summarized in Appendix B (Table B.3).
The sequence data for all the isolated plasmids showed wild type sequence (Figure 3.10).
The data from this project reinforces the fact that it is very difficult to create active Rpd3 mutants
and is consistent with our observations with human HDAC1 (Chapter 3). As an alternative to
identifying a HDAC1-inhibitor bump hole pair, our attention turned to screening the only active
mutant for HDAC1, E98A against SAHA analogs available in the Pflum lab.
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Figure 34: A representative chromatogram of an active mutant. The chromatogram shows
the sequence data obtained for one mutant confirmed from the HDAC flourimetric assay. The
other 19 mutants also had the wild type sequence. The three amino acid residues are boxed
off and shown on top of each chromatogram.

3.3: Development of a high throughput ELISA assay to screen small molecules for bumphole experiments
To screen a library of small molecules for selectivity against the active HDAC1E98A
protein, it was necessary to develop an assay that is high throughput and inexpensive. ELISAs
are luminescence-based assays that utilize luciferin, which is converted to oxyluciferin (Figure
3.11). Briefly, secondary antibody coated plates (G Bioscience) were incubated with a
monoclonal anti-FLAG antibody. Next, lysates from HDAC1-FLAG or the mutant fusion protein
were added and bound to the FLAG epitope. The deacetylase activities of the bound wild type
or mutant protein were monitored by release of luciferin, which was converted to oxyluciferin by
luciferase in the presence of Mg2+ and ATP. The amount of luminescence is directly proportional
to deacetylase activity. Active mutant(s) exhibit high luminescence activity, comparable to wild
type. A small molecule inhibitor of HDAC1 activity should abolish luminescence. Using this
assay, we set out to screen E98A against all SAHA analogs produced in our lab.
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Figure 35: Plate based ELISA assay to determine the deacetylase activity of wild type or
active HDAC1 mutant(s). Secondary antibody coated plates (G bioscience) were incubated
with α-flag antibodies and lysates from HDAC1-FLAG or mutant protein(s). The deacetylase
activity of the HDAC1 or the mutant bound to the plate cleaves the acetyl group from the luciferin
peptide substrate. The developer contains trypsin, which cleaves the peptide bond between
luciferin and the lysine of the deacetylated product. Luciferin is converted to oxyluciferin (star
with GLOW) by luciferase in the presence of Mg2+ and ATP. Upon deacetylation, luciferin was
released and is converted to oxyluciferin. The amount of luminescence is directly proportional to
the deacetylase activity of each tested protein.
3.3.1: ELISA assay is ideal for screening HDAC inhibitors
To assess whether the plate-based ELISA assay was suitable for screening HDAC
inhibitors against E98A for a bump-hole design, the HDAC inhibitor trichostatin A (TSA) was
tested and the amount of deacetylase activity was measured. In addition; the deacetylase
activities of the catalytically active E98A mutant in the presence and absence of TSA were also
determined. Importantly, the deacetylase activity of the negative control (no protein) was
comparable to the assays with HDAC1 and TSA. Wild type HDAC1 and the active E98A mutant
showed high deacetylase activities at 100 and 115%, respectively (Figure 3.12, columns 3 and
4). Importantly, inhibiting HDAC1 or E98A with TSA reduced deacetylase activities to 25% and
28% respectively (Figure 3.12, columns 5 and 6). The no protein control and H141A had low
deacetylase activities even without TSA (Figure 3.12, columns 1 and 2). These combined
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results show that the ELISA assay is suitable for screening small molecules against HDAC1 and
the E98A mutant for selectivity in order to create a bump-hole pair.

Figure 36: Deacetylase activities of wild type or mutant proteins were inhibited by TSA.
HDAC1 wild-type or mutants were expressed as FLAG-tagged fusion proteins and were captured
on α-FLAG bound to secondary antibody coated plates. The deacetylase activity of
immunoprecipitated protein was determined using the luminescence assay. The percent activity
is compared with that of the wild-type protein (100%) with standard errors shown. The
deacetylase activities for each trial are summarized in Appendix B (Table B.4).

3.3.2: Screening SAHA- analogues to create the first HDAC1-inhibitor bump-hole pair
C-2, C-3, C-6, and N-SAHA analogues have half-maximal inhibition activities in the
micromolar range against HeLa nuclear extracts. The ideal bump-hole inhibitor would have poor
activity against wild type proteins [84-86]. These SAHA analogues contain steric bumps and
therefore have the potential to inhibit mutant but not wild type HDACs. Each SAHA analog was
screened against HDAC1E98A using the ELISA assay.
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3.3.2.1 Screening C-2 SAHA analogs

C-2-SAHA analogues, previously synthesized in the Pflum lab have IC50 values of 75-450
µM against HeLa lysates (Table 3.1) [84]. Attaching a bulky substituent at the C-2 position leads
to a dramatic decrease in potency compared to the parent SAHA inhibitor (500-5000 fold
decrease), making this class of bumped SAHA analogues potential candidates.
Table 3.1: HDAC inhibition by SAHA C-2 analogs

a

Values are the means of three experiments with standard error given in parentheses [84].
Structures of SAHA analogs are summarized in Appendix C, Table C.1.
The ELISA assay was used to test the C-2 SAHA analogs mutant for selectivity towards the

active HDAC1E98A. We hypothesized that the glutamic acid at position 98 in HDAC1 acts as
gate keeper and a mutation to alanine would allow for bulkier substituents to access the active
site, as had been observed with kinases [79-81]. Because all C-2 SAHA analogs display halfmaximal inhibitions in the micromolar range (Table 3.1), all analogues were included in an initial
single screen to identify compounds for further evaluation.
As shown in Table 3.1, most C-2-SAHA analogs inhibited the wild type and the active
HDAC1E98A mutant to the same extent, with the exception of the C-2-pentyl and C-2-hexyl
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SAHA analogs. Interestingly, the C-2-hexyl and pentyl SAHA analogs, with the longest
substituents, were more potent against the E98A mutant (39% and 55% remaining activity,
respectively) compared to HDAC1 (95% and 98% activity, respectively). These data suggest
that the E98A mutant could be allowing the bulkier pentyl and hexyl substituents to enter the
active site and possibly gain access to the 14 Å channel. The observed selectivity of C-2-hexyl
and C-2-pentyl SAHA for E98A encouraged us to determine the IC50 values for the two SAHA
analogs
Table 2.2: Percent deacetylase activities for wild type or HDAC1E98A treated with C-2SAHA analogs at indicated concentrations

.aValues were determined from a single screen.
An ideal HDAC1 bump-hole pair, with the active E98A mutant and a SAHA analog, should
demonstrate at least one hundred-fold lower IC50 compared to wild type [78]. To determine
whether C-2-pentyl or C-2-hexyl SAHA showed this level of selectivity towards the E98A mutant
over wild type, the half-maximal inhibition of analog was determined using the ELISA assay as
described (Figure 3.11). C-2-hexyl-SAHA had an IC50 value of 34.5 µM and 171 µM against the
E98A and HDAC1, respectively (Figure 3.13). The half-maximal inhibition of the C-2-pentylSAHA against HDAC1 and E98A was 18.9 µM and 100 µM, respectively (Figure 3.14). These
observed 5-fold changes in IC50 values are not significant enough for a bump-hole pair.
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Figure 37: Deacetylase inhibitory activities of C-2-hexyl-SAHA. HDAC inhibitory
activities of the C-2hexyl-SAHA measured against HDAC1 (circles) or E98A (open
squares). Mean percentage deacetylase activities of three independent trials with standard
errors are shown (as error bars). Deacetylase activities of individual trials are summarized
in Tables B.4 and B.6 in appendix B.

Figure 38: Deacetylase inhibitory activities of C-2-pentyl-SAHA. HDAC inhibitory
activities of the C-2-pentyl-SAHA measured against HDAC1 (circles) or E98A (open
squares). Mean percentage deacetylase activities of three independent trials with standard
errors are shown (as error bars). Deacetylase activities of individual trials are summarized in
Tables B.7 and B.8 in appendix B.
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3.3.2.2: Screening SAHA analogues functionalized at C-3 position

The observation that some C-2 SAHA analogs show selectivity for the active E98A mutant
encouraged us to screen a C-3 library of analogs previously synthesized by Sun Ea Choi (see
Appendix C, Table 3.2 for structures) [86]. Unlike the C-2 library, C-3 SAHA analogs display
half-maximal inhibition in the lower micromolar range (Table 3.3). The decreased (4-2000 folddecrease) in potency for this class of compounds compared to the C-2 analogs suggests that
the C-3 position is less constrained and can be explored for designing isoform selective
inhibitors. Similar to C-2 analogs, we hypothesized that bulkier substituents at C-3 would gain
access to the active site in the E98A mutant compared to the wild type. An initial screen was
done using the ELISA assay to identify hits for further studies (Table 3.2).
Table 3.3: HDAC inhibition by SAHA C-3 analogs

a

Values are the means of three experiments with standard error given in parentheses.

C3-SAHA analogs inhibited both the wild type and the active E98A mutant to the same
extent (Table 3.4). Specifically, the bulkier substituent C-3-butyl and C-3-phenyl-SAHA analogs
abolished deacetylase activites for both the wild type and E98A enzymes to similar levels (50%
versus ~60% respectively). Interestingly, both the C-3-vinyl and C-3-ethyl-SAHA analogs
demonstrated a two-fold selectivity for E98A over in HDAC1. Collectively, our results indicate
that the C-3 library is equally as potent for the E98A mutant and the wild type. We speculate
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that, unlike the C-2-library which showed more preference for the mutant E98A, the C-3-SAHA
analogs are unable to access the 14 Å channel as might be the case with the C-2-library. With
these results, the analogs were not studied for IC50.
Table 3.4: Percent deacetylase activities for wild type or HDAC1E98A treated with
C-3-SAHA analogs at indicated concentrations.

a

Values were determined from a single screen.

3.3.2.3: Screening SAHA analogues functionalized at the hydroxamic acid nitrogen.

Our results from the C-2 library screen encouraged us to screen SAHA analogs
functionalized at the metal binding moiety. Our hypothesis was that since a long carbon chain in
the C-2 library shows preference for the mutants, possibly by accessing the 14 Å channel, the
N-library could also access this channel easily since the metal binding moiety is next to the
channel. Our previous results from mutagenesis studies indicated that residues in the 14 Å
channel are critical for maintaining HDAC1 activity (Chapter 2). Further, selective HDAC1
inhibitors targeting this channel have been created. We thus wondered if E98A would bind NSAHA analogs (see Appendix C, Table 3.2 for a summary of N-SAHA analogs) with the ability to
access the 14 Å channel to allow us to selectively inhibit the mutant over the wild type to
generate a bump-hole pair.
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Table 3.5: HDAC inhibition by N-SAHA analogs

a

Values are the means of three experiments with standard error given in parentheses.* indicates
IC50 value could not be determined due to solubility problems.
Using the ELISA assay, we screened N-SAHA analogs (all synthesized by Dr. Anton) for

ideal candidates for the bump-hole. The HDAC inhibitory activities of the SAHA analogs were
measured using the ELISA chemiluminescence activity assay against the HDAC1 and
thHDAC1E98A mutant.

A single screen was used to determine the potency of the small

molecules (Table 3.6).
Table 3.6: Percent deacetylase activities for wild type or HDAC1E98A treated with NSAHA analogs at indicated concentrations.

a

Values were determined from a single screen.

With the exception of N-methyl-SAHA, all N-SAHA analogs equally inhibited the mutant
E98A and the wild type in the micromolar range (Table 3.6). The half-maximal inhibition for Nbenzyl and N-homobenzyl substituents against the mutant and the wild type were 80 µM and
150 µM, respectively. N-biphenyl-SAHA was two-fold more selective for the mutant (29%
remaining activity) compared to the wild type (57% remaining activity). N-pentyl-SAHA, whose
IC50 against HeLa lysates showed more potency against the wild type and the mutant to the
same extent. Interestingly, the smallest N-SAHA analog, N-methyl-SAHA, was more selective
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for the mutant over the wild type (39% versus 117% remaining activity). The methyl group could
form favorable interactions with amino acids in the 14 Å cavity. With these promising results, we
further characterized the N-methyl-SAHA analog by determining the IC50 value. N-methyl-SAHA
had an IC50 value of 2.5 µM and 11.5 µM against E98A and HDAC1 respectively (Figure 3.15).
This represents a 5-fold selectivity for the mutant over the wild type, which is insufficient bumphole.

Figure 39: Deacetylase inhibitory activities of N-methyl-SAHA. HDAC inhibitory activities
of N-methylSAHA measured against HDAC1 (circles) or E98A (open squares). Mean
percentage deacetylase activities of three independent trials with standard error are shown (as
error bars). Deacetylase activities of individual trials are summarized in Tables B.9 and B.10 in
appendix B.
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3.4: Discussion
Identification of isoform selective HDAC inhibitors is necessary to provide better cancer
therapies. Understanding the individual functions of each HDAC isoform in cancer formation will
facilitate targeted drug design. The crucial function of HDAC1 in growth, development,
proliferation, cell cycle progression and cancer formation makes it an ideal target for inhibitor
design. To understand the involvement of HDAC1 in cancer formation, the bump-hole approach
proposed in this thesis offers great promise if actualized. Unlike, genetic methods, use of small
molecules to inhibit the active site of HDAC1 would allow for temporal, dose-dependent and
reversible control of cancer-related genes influenced by HDAC1. In addition, inhibiting the active
site should not interfere with HDAC1 binding to associated proteins, otherwise needed for
activity, with genetic methods, involving HDAC1 deletions do not offer this advantage.
Towards this goal, we used two different approaches to create the first HDAC1 inhibitor
bump-hole pair that would have allowed the characterization of roles the involvement of HDAC1
in cancer formation. The bump-hole relies on successful creation of a t mutation in the HDAC1
active site, which has been unattainable for the last 10 years in the Pflum lab (Chapter 2). With
only one active mutant in hand (HDAC1E98A), we first explored the creation of active mutants
using the yeast Rpd3 deacetelyase, as an HDAC1 model. The second part of our effort to
create an HDAC1 inhibitor bump-hole pair focused on screening this one active mutant for
selectivity towards a library of small molecule SAHA analogs synthesized in the Pflum lab.
To identify active mutants from a library of Rpd3 mutants, a functional gene reporter screen
dependent on Rpd3 deacetylase activity was developed and optimized. The assay can be
performed both qualitatively and quantitatively. The qualitative X-Gal screen allows for
identification of possible active mutants by observing blue colored colonies. The inactive Rpd3
would be unable to repress β-gal expression to give a blue color compared to the wild type,
which would yield white colonies (Figure 3.4) demonstrating that active mutants can be
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distinguished from inactive mutants by observing color formation. Quantification of the
deacetylase activity for inactive Rpd3 mutants gave a 2.4-fold increase in β-galactosidase
activity (Figure 3.6). These results indicated that the gene reporter assay is suitable for
screening Rpd3 library for active mutants.
We screened a library of 15,000 Rpd3 mutants for activity using the LACZ gene reporter
assay and validated the activity of selected plasmids using the commercially available
fluorescence assay. We envisioned that cells containing active Rpd3 would be transferable to
HDAC1, for use as a bump-hole. Active Rpd3 mutants showed a white color comparable to wild
type (Figure 3.7). The quantified Rpd3 activities for these positive hits with the OPNG assay
gave 2-23–fold increases in β-galactosidase activity (Figure 3.8). Further, these deacetylase
activities were confirmed using the commercially available fluorescence assay (Figure 3.9).
Upon sequencing however, we did not identify any possible mutants (Figure 3.10); only wild
type Rpd3 was observed.
With these results, we turned to the active HDAC1E98A mutant and screened
functionalized SAHA analogs for selectivity to create a HDAC1 inhibitor bump-hole pair. This
approach necessitated the development of a high throughput ELISA assay (Figure 3.11).
Consistent with previous results (Chapter 2), the E98A mutant and wild type displayed high
deacetylase levels, which were abolished by the HDAC inhibitor trichostatin A (Figure 3.12).
These results demonstrate that the ELISA assay is suitable for screening SAHA analogs for
selectivity toward HDAC1 or the E98Amutant.
Sixteen SAHA analogs functionalized at the hyroxamic group, C-2, C-3, and C-6 with IC50
values in the micromolar range were ideal candidates for this screen. An initial screen showed
that most of the SAHA analogs demonstrated equal potencies against both HDAC1 and the
E98A mutant (Figure 3.13). From the initial screen, C-2-hexyl, C-2-pentyl and N-methyl-SAHA
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had 5-fold increases in activity for E98A, respectively, compared to the wild type at single
concentrations (Tables 3.2 and 3.6). We therefore determined the IC50 values for these three
SAHA analogs. C-2 hexyl and pentyl SAHA had IC50 values of 34.5 µM and 19 µM with E98A
respectively, compared to IC50s of 170 µM, with the wild type. These results translate to a 5-fold
increase in selectivity. Similarly, N-methyl SAHA was 5-fold selective for E98A (IC50=2.5 µM)
over wild type (IC50= 11.5 µM). These observed 5-fold increases in selectivity are not ideal for a
bump-hole (The fold-change observed with kinase bump-hole is 100-fold).
An alternative to the bump-hole technique is the isolation of HDAC1 selective isoforms. In
the last year, there has been a tremendous effort in the Pflum lab to develop high throughput
assays, which would allow for identification of isoform selective inhibitors for all the HDAC
isoform (unpublished work). Plans are underway to screen small molecules analogs from the
University of Michigan center. If HDAC1 selective inhibitors are identified, then the selective
inhibitor will replace the bump-hole strategy and achieve the same goal. This approach can also
be extended to other inhibitor selective HDAC isoforms resulting from the same screen.
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3.5: Experimental details
3.5.1: General equipment
Standard biochemical equipment available in the Pflum lab includes centrifuges (Eppendorf
models 5415D and 5810R), a yeast incubator/shaker (Barnstead labline MaxQMini 4000), a
Tecan GENios Plus spectrophotometer and a VWR rocking platform.
3.5.2: Materials
Yeast Nitrogen Base without amino acids, BactoTM Agar, CSM His-Ura and CSM His-UraTrp were purchase from Difco. The rest of lab supplies were generally bought from Sigma
Aldrich or Fisher Scientific.
3.5.3: Yeast strains and plasmids
The pJK1621 reporter plasmid and the FT5 Δrpd3::HIS3 yeast strain were obtained from
Dr. Kevin Struhl.[82] The insert from the YEplac112-Rpd3-LexA-FLAG and YEplac112Rpd3H150AH151A-LexA-FLAG fusion plasmids were generated from the YEplac112-Rpd3-Lex
and YEplac112-Rpd3H150AH151A-LexA [82] plasmids via PCR using the following primers:
Forward primer: CGGGGTACCATGGTATATGAAGCAACACCTTTTGATCCG; reverse primer
CTGGTTAATTATAAATTAGCCATGGCCTTTATCATCATCATCTTTATAATCCAG
CCAGTCGCCGTTGCG. The PCR fragments were cloned into Nco1 digested YEp112 Rpd3Lex –FLAG plasmid using homologous recombination (Chapter 2, section 2.5.6). Plasmids were
confirmed by DNA sequencing.
3.5.4: Primer details
The three-step asymmetric 60 °C-50 °C touchdown PCR method (Chapter 2, section 2.5.3)
was used to create the insert for a yeast library in the YEplac112-Rpd3LexAFLAG plasmid
using the following primers:
KpnRpd3 for: CGGGGTACCATGGTATATGAAGCAACACCTTTTGATCCG
FLAG+100 rev: CCTAATTCACGTTACCCACC
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F214X/F215X for: CTTTCCACAAATATGGTGAGNNXNNXCCTGGCACAGGTGAACTG
F214X/215X rev: CTCACCATATTTGTGGAAAGAAC
Rpd3L281 (NcoI) for:
CTCCTTGTCCGGCGATCGTNNXGGTTGCTTTAATCTTTCTATGGAAGGCC
Where X=G or T
3.5.5: Mini-prep of DNA from yeast cells
Approximately 100 mm3 cell were obtained from a yeast plate using a sterile Pasteur
pipette. The cells were dissolved in 1 mL ddH2O and spun at 4200 rpm for 5 minutes. The
supernatant was removed by aspiration and the cell pellet was resupended in 0.2 mL of
Triton/SDS solution (10 mM Tris-Cl, pH 8.0, 2% (v/v) Triton X-100, 1% (w/v) SDS, 100 mM and
1 mM EDTA); the solution was filtered with 0.2 µM filters to sterilize. To the cell mixture, 1:1
equilibrated phenol: chloroform (0.2 mL) and glass beads (0.3 g) were added. The mixture was
vortexed for 2 minutes at room temperature and TE buffer (0.2 mL; 10 mM Tris, pH 8.0, 1 mM
EDTA) was added, followed by spinning at 5 minutes at 13200 rpm. The top aqueous layer was
transferred to a clean epitube containing 1 mL ethanol, mixed by inversion, and spun for another
5 minutes at 13200 rpm. The supernatant was removed and the remaining DNA pellet was
dissolved into 400 µL TE buffer containing 20 µg/mL RNase A. The mixture was incubated for 5
minutes at room temperature and centrifuged at 13200 rpm for 5 minutes. The aqueous layer
was transferred into an epitube containing 1 mL ethanol and 80 µL 10 M ammonium acetate.
This solution was spun at 13200 rpm for 5 minutes and the ethanol was discarded. The DNA
pellet was dissolved in 20 µL ddH2O for storage at -20 °C.
3.5.6: Yeast transformation of plasmid DNA
Approximately 10 yeast colonies from a fresh growth plate were transferred into a solution
containing 333 µL 60% PEG 3350, 50 µL 1 M DTT (dithiothreitol), 50 µL of 2 N lithium acetate,
and 67 µL water (this mixture is sufficient for 5 transformations). Cells were mixed thoroughly by
vortexing to disperse the PEG. To this mixture, 10 µL 10 mg/mL salmon sperm DNA and 1 µL
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0.5 µg/mL plasmid DNA was added. The mixture was incubated on ice for 30 minutes, then at
45 °C for 45 minutes, and finally transferred to ice for a further 5 minutes. Aliquots (100 µL)
were plated on yeast plates with appropriate selection medium (CSM-His-Ura in the case of the
pJK1521 plasmid; or CSM-His-Trp-Ura, in the case of pJK1561 plus Rpd3 expression plasmids)
(Difco). Cells were grown at 30 °C for 3-7 days until colonies were observed. A note about
making of these yeast plates: Yeast plates were prepared by mixing Yeast Nitrogen Base
(6.7%), CSM-His-Ura-Trp or CSM-His-Ura (0.77%), dextrose (5%) and 2% BactoAgar in distilled
water. The mixture was autoclaved and poured into petri dishes and allowed to solidify. Plates
were used immediately or stored at 4 °C until use. Yeast growth media was prepared in a
similar manner but without the BactoAgar.
3.5.7: X-Gal agarose overlay assay
For X-Gal assay optimization (Section 3.2.1.2 and figure 3.5), a single colony from a yeast
transformation (section 3.5.8) was re-dissolved in 20 µL distilled water and spotted on wells. To
make the wells, yeast nitrogen base (6.7%), CSM-His-Ura-Trp or CSM-His-Ura (0.77%),
dextrose (5%) and 2% BactoAgar were mixed in distilled water, autoclaved, poured into 96-well
white plates (100 µL per well) using a pipette, and allowed to solidify. After spotting the wells,
cells were allowed to grow for 2-3 days at 30 °C. To perform the X-Gal overlay assay, lowmelting agarose (5 mg/mL, Life technologies # No. 15517-022) was added to a 10 mL stock
solution consisting of 0.5 M potassium phosphate buffer, pH 7.0, 6% DMF and 1% SDS. The
0.5M potassium phosphate buffer pH 7.0 was prepared by mixing 61 mL 1M K2HPO4 , 39 mL 1
M KH2PO4 and 100mL distilled water, followed by filtering to sterilize. DMF and SDS help to
permeabilize the cell. The agarose mixture was boiled by microwaving for approximately 1
minute. To the warm mixture, X-Gal (0.1-0.5 mg/mL), 50 µL β-mercaptoethanol, and 100 µM
trichostatin A (or 2% DMSO control) were added. Using a Pasteur pipette, the mixture was
transferred to the surface of the well (200 µL was enough to cover the surface). The agar was
allowed to cool and solidify and then incubated at 30 °C until blue color was observed (usually
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4-6 hours). The colonies were retrieved by scraping off the top X-gal agar, and used for the
ONPG assay (section 3.5.8)
3.5.8: Liquid β-galactosidase ONPG assay
For ONPG assay optimization (Section 3.2.1.3 and figure 3.6), colonies were retrieved from
beneath the agar surface of wells (section 3.5.7) using a Pasteur pipette. Colonies were
separately grown overnight at 30 °C with shaking at 200 rpm in 0.5-1.5 mL yeast media (section
3.5.6) containing the appropriate amino acid complementation; CSM-His-Ura (for FT5
Δrpd3::HIS3 expressing pJK1621) or CSM-His-Trp-Ura (for FT5 Δrpd3::HIS3 expressing
pJK1621 and YEplac112-Rpd3LexAFLAG). The overnight culture was diluted to A600=0.1, 100
µM trichostatin A added (or 2% DMSO for control), and it was grown to A600=0.4-1.0. Cells were
collected by spinning at 13200 rpm for 10 minutes at room temperature. The medium was
removed by aspiration and the cell pellet was resuspended into 0.5 mL of buffer Z, (0.1 M
Na2HPO4.7H2O, pH 7.0, 0.04 M NaH2PO4, 0.1 M KCl, 2 M MgSO4 and 2.7 µL/mL βmercaptoethanol). SDS (25 µL 0.1%), chloroform (20 µL) and 100 µL of 4 mg/mL 2-Nitrophenyl
β-D-galactopyranoside (ONPG, from SIGMA) was added to the mixture, followed by vortexing
for 30 seconds. The mixture was incubated for 1 hour or until yellow color appeared. Na 2CO3
(100 µL 1 M) was added to quench the reaction. Cell debris was removed by spinning at 6000
rpm for 1 minute and the OD420 measured from a 300 µL sample of the supernatant. Normalized
units of β-galactosidase activity were calculated using the following equation: Units = (OD420 x
1000) / (OD600 x T x V), where T= ONPG incubation time in minutes, V= volume used to
measure absorbance, OD420 in µL and OD600 is the absorbance of diluted overnight culture after
growth for several hours. The fold change in β-gal activity for each mutant was normalized to
that of the wild type Rpd3 (Normalized units were set to one).
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3.5.9: Procedure for screening Rpd3 library
3.5.9.1 Rpd3 library transformation
Plasmid DNA containing Rpd3 mutants was transformed as described in section 3.5.6.
Briefly, Approximately 10 yeast colonies of FT5 Δrpd3::HIS3 from a fresh growth plate were
transferred into a solution containing 333 µL 60% PEG 3350, 50 µL of 1 M DTT (dithiothreitol),
50 µL of 2 N lithium acetate, and 67 µL water (this mixture is sufficient for 5 transformations).
Cells were mixed thoroughly by vortexing to disperse PEG. To the mixture, 10 µL 10 mg/mL
salmon sperm DNA and 1 µL 0.5 µg/mL plasmid DNA were added. The mixture was incubated
on ice for 30 minutes, and then at 45 °C for 45 minutes, and finally transferred to ice for a further
5 minutes. Aliquots (100 µL) were plated on yeast plates with amino acid complementation
CSM-His-Trp-Ura. Cells were grown at 30 °C for 3-7 days until colonies were observed. Yeast
plates were stored at -4 °C until use.
3.5.9.2 X-Gal overlay assay for Rpd3 library
X-Gal overlay solution was prepared and overlaid on yeast plates from section 3.5.9.1 as
described in section 3.5.7. Plates were overlaid with X-Gal solution using a Pasteur pipette (10
mL was enough to cover the surface of the plate). The agar was allowed to cool and solidify and
then incubated at 30 °C until blue color was observed (usually 4-6 hours). White colonies were
retrieved from agar by scrapping off the top agarose solid and separately inoculated in 2 mL
yeast growth medium with amino acid complementation CSM-His-Trp-Ura.
3.5.9.3: Liquid β-galactosidase ONPG assay for Rpd3 library
White colonies identified from section 3.5.9.2 were separately grown in 2 mL yeast growth
medium with amino acid complementation CSM-His-Trp-Ura overnight at 30 °C with shaking at
200 rpm. ONPG assay was conducted as described in section 3.5.8.
3.5.10: Yeast lysis protocol
Yeast cells were grown at 30 ºC overnight in 5 mL CSM-His-Ura (for FT5 Δrpd3::HIS3
expressing pJK1621) or CSM-His-Trp-Ura (for FT5 Δrpd3::HIS3 expressing pJK1621 and
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YEplac112-Rpd3LexAFLAG) with shaking. Cells were collected by spinning at 6000 rpm for 5
minutes. The cell pellet was resuspended in 1 mL yeast lysis buffer F (20 mM HEPES, pH 7.9,
150 mM NaCl, 10% glycerol) and 3 g glass beads were added. Protease inhibitor cocktail set V
(1X, Calbiochem) was added and cells were lysed by a successive 6-8 rounds of vortexing at
maximum settings for 30 seconds, followed by cooling on ice for 45 seconds. After the last
vortex cycle, cells were incubated on ice for 2 min to allow glass beads to settle. The cell extract
was transferred to a clean epitube and cell lysates (supernatant) were recovered by spinning at
6000 rpm for 5 minutes, followed by immediate use or storage at -80 °C until use.
3.5.11: Histone deacetylase assay and immunoprecipitation
Lysates prepared from the FT5 Δrpd3::HIS3 yeast strain expressing FLAG tagged Rpd3LexA fusions were prepared as described in section 3.5.10. Expressed wild-type and mutant
FLAG-tagged Rpd3 proteins were immunoprecipitated from the lysates (200 µg of extract for
each immunoprecipitation) by incubating with 15 μL of an anti-FLAG agarose bead slurry
(Sigma) in buffer F (1 mL 20 mM HEPES, pH 7.6, 1 mM EDTA, 150 mM NaCl, 20% glycerol)
for 2 hours at 4 °C with inversion. After 2 hours, beads were recovered by spinning at 4000 rpm
for 5 minutes at 4 °C. The supernatant was removed and beads washed three times in 1 mL
buffer F by a successive spinning and supernatant removal process. The beads were split into
half: one half was used for the HDAC assay, the other half was used for gel analysis (Section
3.5.11). The deacetylase activity of immunoprecipitated proteins was measured using the Fluor
de Lys fluorescence activity assay kit (Biomol) as described in chapter 2 (section 2.5.16).
3.5.12: SDS-PAGE and Western
SDS-PAGE was run in s 10% gel as described in chapter 2 (section 2.5.14). The gel was
transferred to PVDF membranes as described in chapter 2 (section 2.5.15), probed with antiLexA antibodies (Promega) and visualized as described in chapter 2 (section 2.5.16).
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3.5.13: Plate based ELISA assay
Anti-mouse secondary antibody coated plates (G Biosciences) were washed three times
with 1X TBST wash buffer (0.2 M Tris base, 1.37 M NaCl, 0.2 M KCl and 0.0005% Tween). The
anti-FLAG antibody (Sigma) was dissolved in 1XTBST containing 3% BSA to a final
concentration of 10 µg/mL and 100 µL was added to the plate and was incubated at room
temperature for 1 hour with rocking (Rocking platform VWR) or overnight at 4 °C. The antibody
solution was removed by inverting the plate and the plate was washed ten times wish 1XTBST
wash buffer using a squirt bottle. Lysates of FLAG-fusion wild type or mutant proteins were
prepared as described in chapter 2, (section 2.5.13) and were diluted in 1XTBST containing
10% non-fat dry milk (3 % BSA can also be used) to a final concentration of 10 µg/mL. An
aliquot (100 µL) was added to the plate and incubated for 1 hour with rocking at 4 °C. The
lysates were removed by inversion and washed ten times in 1XTBST using a squirt bottle.
GloTM substrate (25µL; Promega) was added and incubated for 25 minutes without shaking at
room temperature, after which the luminescence was determined using the Genios plate reader
(Tecan). The luminescence signal for each mutant was normalized to the wild type (set at
100%) and standard error from at least four independent trials are shown in the appendix B.4.
3.5.14: Screening SAHA analogs using 96-well plate ELISA assay
The screen was done as described in section 3.5.10 with some modifications. After removal
of the lysates and washing, the small molecule was dissolved in DMSO (see appendix B Tables,
B.5-B.10 and Tables 3.2, 3.4 and 3.6 for concentrations) and incubated for 15 minutes. The
DMSO concentration was kept at a constant 2% for all reactions. Then, 25 µL of the GloTM
substrate (Promega) was added and left for 25 minutes without shaking, after which the
luminescence was determined using the Genios plate reader. Several controls were included; a
DMSO control (2%) for both the wild type and mutant protein and a no protein control with 2%
DMSO for background luminescence. The normalized deacetylase activity was determined by
subtracting the amount of luminescence from the no protein control with 2% DMSO. The
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percent activity at each small molecule concentration was calculated by determining the percent
luminescence activity in the presence of inhibitor versus absence of inhibitor.
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APPENDIX A.
Table A.3: Percent deacetylase activities for HDAC1 alanine mutants.
Protein

Trial1

Trial 2

Trial 3

Trial 4

No protein

6

25

22

13

Wild-Type

100

100

100

100

H141A

18

20

25

V19A

44

31

Y23A

30

Y24A

Trial 5

Trial 6

Mean

S.E

ND

ND

16

4.0

100

ND

100

0.0

15

20

ND

19

1.5

25

37

17

ND

31

4.5

69

31

25

36

18

35

7.0

23

49

20

35

20

8

26

6.0

M30A

20

5

36

18

ND

ND

20

6.0

R34A

42

41

13

17

42

ND

31

6.5

I35A

5

4

3

14

3

ND

5.8

2.0

R36A

38

26

16

26

20

ND

25

4.0

S113A

71

70

51

66

51

ND

62

4.0

L139A

40

39

37

41

ND

ND

39

1.0

C151A

11

21

39

11

30

15

21

4.5

Y303A

10

6

7

9

2

ND

6.7

1.5

HDAC1 wild-type or alanine mutants were expressed as FLAG-tagged fusion proteins and were
immunoprecipitated with anti-FLAG-agarose bead resin. The immunoprecipitated proteins were
tested for deacetylase activity using an in vitro fluorescence assay, as described in section
2.5.16. The mean percent activity for each independent trial compared to that of the wild-type
protein (100%) with standard error (S.E) is shown. ND = Not determined (Data shown in Figures
2.9 and 2.11 in text).
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Table 4: Percent deacetylase activities for HDAC1 rescue mutants
Protein

Trila1

Trial 2

Trial 3

Trial 4

Trial 5

Trial 6

Mean

S.E

No protein

18

11

2.7

3.0

1.9

ND

7.4

3.1

Wild-Type

100

100

100

100

100

ND

100

0.0

Y23F

5

7

13

25

10

ND

12

3.5

Y24F

57

31

81

44

69

ND

56

9.0

R34K

17

16

14

18

7

28

17

3.0

R36K

29

41

30

ND

ND

33

3.5

C151S

33

25

29

30

31

ND

30

1.0

Y303F

50

33

37

31

ND

ND

38

4.0

ND

HDAC1 wild-type or alanine mutants were expressed as FLAG-tagged fusion proteins and were
immunoprecipitated with anti-FLAG-agarose bead resin. The immunoprecipitated proteins were
tested for deacetylase activity by an in vitro fluorescence assay, as described in section 2.5.16.
The mean percent activity for each independent trial compared with that of the wild-type protein
(100%) with standard error (S.E) is shown. ND = Not determined (Data shown in figure 2.12 in
text).
.
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Table 5: Percentage remaining HDAC activity after incubation of acetate with HDAC1
Concentration (M)

Trial 1

Trial 2

Trial 3

Trial 4

Trial 5

Mean

S.E

2.5 x 10-2

10

22

15

23

21

18

2.4

1.25 x 10-2

36

31

31

24

31

31

2

6.25 x 10-3

55

55

44

61

50

53

2.8

3.125 x 10-3

63

83

81

74

ND

75

4.5

1.56 x 10-3

80

107

98

98

ND

96

5.6

Deacetylase activity of wild type was determined at each sodium acetate concentration using an
in vitro fluorescence assay as described in section 2.5.16. The percentage deacetylase activity
of each independent trial, mean percentage deacetylase activity, and standard error (S.E) at
each acetate concentration are shown. ND = Not determined.
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Figure 40: IC50 Curve of Acetate with wild type HDAC1. A plot showing the percentage
deacetylase activity of wild type HDAC1 versus acetate concentration. Data was fit to a
sigmoidal curve using Kaleidograph 4.0 (Synergy Software) to determine the IC50. The inset is
the results of the data analysis and the calculated IC50 (m3 in molar) is given with error.
Graph included in Figure 2.13, Figure 2.14, and Table 1.1.
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Table 6: Percentage remaining HDAC activity after incubation of acetate with
HDAC1R34A
Concentration (M)

Trial 1

Trial 2

Trial 3

Trail 4

Trial 5

Mean

S.E

2.0 x 10-1

7.8

12

20

20

8

14

3

6.6 x 10-2

33

26

25

24

21

26

4.5

2.25 x 10-2

50

40

64

42

38

47

8.7

7.4 x 10-3

73

72

70

65

81

73

12

2.46 x 10-3

96

82

82

82

116

92

16

Deacetylase activity of HDAC1R34A mutant was determined at each sodium acetate
concentration using an in vitro fluorescence assay, as described in section 2.5.16.The
percentage deacetylase activity of each independent trial, mean percentage deacetylase activity
and standard error (S.E) at each acetate concentration are shown.
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Figure 41: IC50 Curve of Acetate with HDAC1R34A. A plot showing the percentage deacetylase
activity of HDAC1R34A versus acetate concentration. Data was fit to a sigmoidal curve using
Kaleidograph 4.0 (Synergy Software) to determine the IC50. The inset is the results of the data
analysis and the calculated IC50 (m3 in molar) is given with error. Graph included in Figure 2.13 and
Table 1.1.
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Table 7: Percentage remaining HDAC activity after incubation of acetate with
HDAC1Y23A.
Concentration (M)

Trial 1

Trial 2

Trial 3

Trial 4

Mean

S.E

2.0 x 10-1

7.5

23

20

13

16

3

6.6 x 10-2

17

40

25

25

27

4.5

2.25 x 10-2

44

50

64

55

53

8.7

7.4 x 10-3

75

55

70

71

68

12

2.46 x 10-3

84

89

82

90

86

16

Deacetylase activity of HDAC1Y23A mutant was determined at each sodium acetate
concentration using an in vitro fluorescence assay, as described in section 2.5.16. The
percentage deacetylase activity of each independent trial, mean percentage deacetylase activity
and standard error (S.E) at each acetate concentration are shown.
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Figure 42: IC50 Curve of Acetate with HDAC1Y24A: A plot showing the percentage
deacetylase activity of HDAC1R34A versus acetate concentration. Data was fit to a
sigmoidal curve using Kaleidograph 4.0 (Synergy Software) to determine the IC50. The
inset is the results of the data analysis and the calculated IC50 (m3 in molar) is given
with error. Graph included in Figure 2.14 and Table 1.1.
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Table 8: Percentage remaining HDAC activity after incubation of acetate with
HDAC1Y24A.
Concentration (M)

Trial 1

Trial 2

Trial 3

Mean

S.E

2.0 x 10-1

13

23

8

15

4.4

6.6 x 10-2

25

32

17

24

4.3

2.25 x 10-2

55

46

44

48

3.3

7.4 x 10-3

71

60

75

69

4.4

2.46 x 10-3

80

83

84

82

1.2

Deacetylase activity of HDAC1Y24A mutant was determined at each sodium acetate
concentration using an in vitro fluorescence assay, as described in section 2.5.16. The
percentage deacetylase activity of each independent trial, mean percentage deacetylase activity
and standard error (S.E) at each acetate concentration are shown.
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Figure 43: IC50 Curve of Acetate with HDAC1Y24A. A plot showing the percentage
deacetylase activity of HDAC1Y24A versus acetate concentration. Data was fit to a sigmoidal
curve using Kaleidograph 4.0 (Synergy Software) to determine the IC50. The inset is the results
of the data analysis and the calculated IC50 (m3 in molar) is given with error. Graph included in
Figure 2.14 and Table 1.1.

99
Table A.9: Percentage remaining HDAC activity after incubation of acetate with
HDAC1R36A.
Concentration (M)

Trial 1

Trial 2

Trial 3

Mean

S.E

2.0 x 10-1

16

24

16

19

2.6

6.6 x 10-2

37

21

37

32

5.3

2.25 x 10-2

46

39

46

44

2.3

7.4 x 10-3

60

55

60

58

1.6

2.46 x 10-3

77

72

77

75

1.6

Deacetylase activity of HDAC1R36A mutant was determined at each sodium acetate
concentration using an in vitro fluorescence assay, as described in section 2.5.16. The
percentage deacetylase activity of each independent trial, mean percentage deacetylase activity
and standard error (S.E) at each acetate concentration are shown.

100

Figure 44: IC50 Curve of Acetate with HDAC1R36A. A plot showing the percentage deacetylase
activity of HDAC1R36A versus acetate concentration. Data was fit to a sigmoidal curve using
Kaleidograph 4.0 (Synergy Software) to determine the IC50. The inset is the results of the data
analysis and the calculated IC50 (m3 in molar) is given with error. Graph included in Figure 2.13 and
Table 1.1.
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Table A.10: Percentage remaining HDAC activity after incubation of acetate with
HDAC1C151A.
Concentration (M)

Trial 1

Trial 2

Trial 3

Mean

S.E

2.0 x 10-1

10

23

10

14

4.3

6.6 x 10-2

20

33

20

24

4.3

2.25 x 10-2

38

39

38

38

0.3

7.4 x 10-3

58

62

58

59

1.3

2.46 x 10-3

72

86

84

81

4.3

Deacetylase activity of HDAC1C151A mutant was determined at each sodium acetate
concentration using an in vitro fluorescence assay, as described in section 2.5.16. The
percentage deacetylase activity of each independent trial, mean percentage deacetylase activity
and standard error (S.E) at each acetate concentration are shown.
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Figure 45: IC50 Curve of Acetate with HDAC1C151A. A plot showing the percentage
deacetylase activity of HDAC1C151A versus acetate concentration. Data was fit to a
sigmoidal curve using Kaleidograph 4.0 (Synergy Software) to determine the IC50. The
inset is the results of the data analysis and the calculated IC50 (m3 in molar) is given with
error. Graph included in Figure 2.14 and Table 1.1.
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Table A.11: Percentage remaining HDAC activity after incubation of acetate with
HDAC1F205Y.
Concentration (M)

Trial 1

Trial 2

Trial 3

Trail 4

Mean

S.E

2.5 x 10-2

19

26

21

26

23

1.7

1.25 x 10-2

35

33

33

ND

34

0.6

6.25 x 10-3

50

47

47

60

51

3.1

3.125 x 10-3

65

88

88

73

79

5.0

1.56 x 10-3

102

99

99

97

99

1.2

Deacetylase activity of HDAC1F205Y mutant was determined at each sodium acetate
concentration using an in vitro fluorescence assay as described in section 2.5.16. The
percentage deacetylase activity of each independent trial, mean percentage deacetylase activity
and standard error (S.E) at each acetate concentration are shown. ND = Not determined.
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Figure 46: IC50 Curve of Acetate with HDAC1F205Y. A plot showing the percentage
deacetylase activity of HDAC1F205Y versus acetate concentration. Data was fit to a sigmoidal
curve using Kaleidograph 4.0 (Synergy Software) to determine the IC50. The inset is the results
of the data analysis and the calculated IC50 (m3 in molar) is given with error. Graph included in
Figure 2.13 and Table 1.1.
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APPENDIX B.

Table B.12: Quantitative inhibition of Rpd3 activity (data obtained by Sujith Weerasighe)
Sample

Trial 1

Trial 2

Trial 3

Trial 4

Trial 5

Mean

S.E

LACZ reporter

3.49

2.92

3.40

6.49

5.95

4.45

0.73

LACZ reporter + 2.87
TSA 100µM

2.78

4.59

4.81

6.21

4.25

0.65

Wt Rpd3

1.00

1.00

1.00

1.00

1.00

1.00

-

Wt Rpd3 +

1.42

1.47

2.16

1.58

1.44

1.61

0.12

Rpd3 mutant

2.32

2.02

2.90

3.30

4.25

2.96

0.39

Rpd3 mutant +

2.21

2.50

3.20

4.81

5.2

3.58

0.61

TSA 100µM

TSA 100µM

LACZ reporter plasmid, pJK1621, was transformed with or without wild type Rpd3 or
catalytically inactive Rpd3 mutant as LexA-FLAG fusions into FT5 Δrpd3::HIS yeast strain.
Transformed cell were grown with or without TSA for 6h at 30°C and β-galactosidase activity
was measured quantitatively using ONPG as the substrate. Relative fold changes in βgalactosidase activity was calculated with respect to wild type Rpd3 as described and mean fold
change observed with three independent trial is shown with standard error (S.E). ND= Not
determined. Data shown in figure 3.6 in the text.
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Table 13: A representative quantitative ONPG inhibition of Rpd3 mutant(s) activity.
WildType

Rpd3H150A

1

2

3

4

5

6

7

8

9

10

H151A
Trial

1.0

4.4

4.1

4.0

1.2

2.7

3.7

7.1

6.3

3.3

4.4

1.4

1.0

4.7

3.5

4.5

1.5

2.5

3.9

6.5

6.5

3.5

4.7

1.2

1
Trial
2

LACZ reporter plasmid, PJK1621, was transformed with or without wild type Rpd3 (or
catalytically inactive Rpd3) or plasmid DNA from Rpd3 library mutant as LexA-FLAG fusions into
FT5 Δrpd3::HIS yeast strain. Transformed cells were grown for 6h at 30°C and β-galactosidase
activity was measured quantitatively using ONPG as the substrate. Relative fold changes in βgalactosidase activity was calculated with respect to wild type Rpd3 as described and data from
2 trials is shown. Data shown in Figure 3.8 of the text.

Table 14: Deacetylase activity of immunoprecipitated wild type or Rpd3 mutants
Wild type

RpdH150A

3

4

5

6

10

H151A
Trial 1

100

16

86

33

26

79

21

Trial 2

100

25

99

40

20

80

30

Lysates were prepared from FT5 Δrpd3::HIS3 yeast strain expressing FLAG tagged Rpd3-LexA
fusion proteins and immunoprecipitated as described in section 3.8. The deacetylase activity of
immunoprecipitated proteins was measured using Fluor de Lys fluorescence activity assay kit.
Percentage deacetylase activity for two trials is shown. Data shown in Figure 3.9 of the text.
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Table 15: Validation of plate based ELISA assay

Protein
No protein
H141A
HDAC1
E98A
HDAC1 + TSA

Trial 1
24
10
100
110
25

Trial 2
10
15
100
119
20

Trial 3
21
10
100
120
25

Trial 4

19

Mean
19
10
100
115
22

S.E
3.0
1.4
2.3
1.6

E98A + TSA

25

30

24

34

28

2.3

21
8
100
114

Deacetylase activity was determined using ELISA assay as described (Chapter 3, section
3.5.14). Percentage deacetylase activity of each independent trial, mean percentage
deacetylase activity and standard error (S.E) are shown. Data shown in Figure 3.12 of the text.

Table 16: Percentage remaining HDAC activity after incubation of SAHA C-2-hexyl with
HDAC1
Concentration (M)
4.8 x 10-2
2.4 x 10-2
1.2 x 10-2
6.0 x 103
3.0 x 10-3

Trial 1
35
57
63
72
75

Trial 2
21
39
52
64
90

Trial 3
31
23
66
73
96

Mean
30
40
60
70
87

S.E
4.1
9.8
4.2
2.8
6.2

Deacetylase activity was determined at each SAHA C-2-hexyl concentration using ELISA assay
as described (Chapter 3, section 3.5.14). Percentage deacetylase activity of each independent
trial, mean percentage deacetylase activity and standard error (S.E) at each concentration are
shown. Data shown in Figure 3.13 of the text.
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Table 17: Percentage remaining HDAC activity after incubation of SAHA C-2-hexyl with
HDAC1E98A

Concentration (M)
1.2 x 10-2
6.0 x 10-3
3.0 x 10-3
1.5 x 10-3
7.5 x 10-4

Trial 1
32
43
73
73
91

Trial 2
14
40
47
67
80

Trial 3
6
14
46
60
94

Mean
17
32
55
67
88

S.E
7.6
9.2
8.8
3.7
4.2

Deacetylase activity was determined at each SAHA C-2-hexyl concentration using ELISA assay
as described (Chapter 3, section 3.5.14). Percentage deacetylase activity of each independent
trial, mean percentage deacetylase activity and standard error (S.E) at each concentration are
shown. Data shown in Figure 3.13 of the text.

Table 18: Percentage remaining HDAC activity after incubation of SAHA C-2-pentyl with
HDAC1

Concentration (M)
2.4 x 10-2
1.2 x 10-2
6.0 x 10-3
3.0 x 10-3
1.5 x 10-3

Trial 1
24
38
65
97
94

Trial 2
29
44
68
71
94

Trial 3
35
46
57
68
94

Mean
30
43
63
78
94

S.E
3.1
2.4
3.2
9.2
-

Deacetylase activity was determined at each SAHA C-2-pentyl concentration using ELISA
assay as described (Chapter 3, section 3.5.14). Percentage deacetylase activity of each
independent trial, mean percentage deacetylase activity and standard error (S.E) at each
concentration are shown. Data shown in Figure 3.14 of the text.
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Table 19: Percentage remaining HDAC activity after incubation of SAHA C-2-pentyl with
HDAC1E98A
Concentration (M)
6.0 x 10-3
3.0 x 10-3
1.5 x 10-3
7.5 x 10-4
3.75 x 10-4

Trial 1
15
23
66
77
88

Trial 2
33
51
62
83
95

Trial 3
22
34
48
54
74

Mean
23
36
58
71
85

S.E
5.2
8.1
5.4
8.8
6.1

Deacetylase was determined at each SAHA C-2-pentyl concentration using ELISA assay as
described (Chapter 3, section 3.5.14). Percentage deacetylase activity of each independent
trial, mean percentage deacetylase activity and standard error (S.E) at each concentration are
shown. Data shown in Figure 3.14 of the text.

Table 20: Percentage remaining HDAC activity after incubation of N-methyl SAHA with
HDAC1
Concentration (M)
2.56 x 10-3
1.28 x 10-3
6.4 x 10-4
3.2 x 10-4
1.6 x 10-4

Trial 1
18
52
65
79
113

Trial 2
40
44
51
79
87

Trial 3
20
68
54
99
86

Mean
26
54
56
85
95

S.E
7.0
7.0
4.2
6.6
8.8

Deacetylase activity was determined at each N-methyl SAHA concentration using ELISA assay
as described (Chapter 3, section 3.5.14). Percentage deacetylase activity of each independent
trial, mean percentage deacetylase activity and standard error (S.E) at each concentration are
shown. Data shown in Figure 3.15 of the text.

110
Table 21: Percentage remaining HDAC activity after incubation of N-methyl SAHA with
HDAC1E98A
Concentration (M)
6.4 x 10-4
3.2 x 10-4
1.6 x 10-4
8.0 x 10-5
4.0 x 10-5

Trial 1
38
62
81
83
98

Trial 2
35
44
54
70
85

Trial 3
8
29
39
78
84

Mean
27
57
58
77
90

S.E
9.5
9.5
12
3.7
4.5

Deacetylase was determined at each N-methyl SAHA concentration using ELISA assay as
described in Chapter 3, section 3.5.14. Percentage deacetylase activity of each independent
trial, mean percentage deacetylase activity and standard error (S.E) at each concentration are
shown. Data shown in Figure 3.15 in text.
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APPENDIX C.
Figure 47: Structures of SAHA C2 analogs
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Figure 48: Structures ofHSAHA C3 analogs
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Figure 49: Structures of N-SAHA analogs
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Histone deacetylase 1 (HDAC1) has been linked to cell growth and cell cycle regulation,
which makes it a widely recognized target for anticancer drugs. The 14 Å channel of Class 1
HDAC isotypes has long being hypothesized to be the exit cavity for acetate following
deacetylation. The amino acids lining this cavity are very similar among the HDAC isoforms,
suggesting the role of the cavity is relevant to all HDACs proteins Importantly, HDAC1 selective
inhibitors designed to fit the 14Å channel have been designed. To understand the importance of
the 14Å channel to HDAC1 activity, we used an alanine scan to determine the influence of
residues in the 14 Å channel of the HDAC1. The mutation of eleven channel residues to alanine
led to a significant reduction in deacetylase activity. Acetate competition experiment revealed
that, charged residues lining the 14Å affect HDAC1 binding to acetate. The combined results
reveal 14Å channel residues critical for HDAC1 activity and acetate escape. With no
crystallographic information on HDAC1 available, these findings provide important insight HDAC
inhibitor design.
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Understanding the involvement of HDAC1 in cancer formation is critical in developing
selective inhibitors. Towards this goal, we did extensive studies to create a HDAC1 bump-hole
inhibitors pair as an alternative to genetic methods which are limited in their usage to
characterize HDAC1 function. We developed and validated a histone deacetylase dependent
screen in the yeast Rpd3 protein. Using this screen screened a library of Rpd3 mutants with the
aim of isolating active mutants for the bump-hole. Of the 15, 000 colonies screened none had a
mutation. We focused on testing the active E98A mutant against SAHA inhibitor analogs
present in our lab. C-2, C-3 and N-SAHA analogs were screened using a plate based ELISA
assay which we developed and validated. All SAHA analogs screened did not qualify for a
HDAC1-bump inhibitor system.
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